Riot Blockchain (RIOT) 10-K 17 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Apr. 13, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Riot Blockchain, Inc.
Entity Central Index Key	1,167,419
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		13,417,132
Entity Public Float			$ 21.9

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets (Note 1):
Cash and cash equivalents	$ 41,651,965	$ 5,529,848
Short-term investments		7,506,761
Prepaid expenses and other current assets	538,812	219,991
Digital currencies	200,164
Current assets of discontinued operations (Note 10)	44	486,890
Total current assets	42,390,985	13,743,490
Property and equipment, net (Notes 3 and 13)	4,294,166	5,538
Intangible rights acquired (Note 2)	754,244
Long-term investments (Note 4)	3,000,000
Other long-term assets, net (Note 5):
Patents	509,649	550,799
Goodwill	1,186,496	387,239
Convertible note	200,000
Noncurrent assets of discontinued operations (Note 10)		2,353,749
Total assets	52,335,540	17,040,815
Current liabilities:
Accounts payable	410,029	253,817
Accrued expenses	216,883	306,195
Notes and other obligations, current (Note 6)	135,574	139,611
Deferred revenue, current portion (Note 9)	96,698	96,698
Current liabilities of discontinued operations (Note 10)	181,340	258,819
Total current liabilities	1,040,524	1,055,140
Deferred revenue, less current portion (Note 9)	968,617	1,065,316
Deferred income tax liability (Note 11)	699,000
Total liabilities	2,708,141	2,120,456
Commitments and contingencies (Notes 2 and 12)
Stockholders' equity (Notes 7, 8 and 13):
Common stock, no par value, 170,000,000 (2017) and 60,000,000 (2016) shares authorized; shares issued 11,622,112 (2017) and 4,503,971 (2016)	180,387,518	124,775,635
Accumulated deficit	(139,263,480)	(109,855,276)
Total Riot Blockchain stockholders' equity	48,869,304	14,920,359
Non-controlling interest (Note 2)	758,095
Total equity	49,627,399	14,920,359
Total liabilities and stockholders' equity	52,335,540	17,040,815
2% Convertible Preferred Stock Series A [Member]
Stockholders' equity (Notes 7, 8 and 13):
Preferred Stock, no par value, 15,000,000 (2017) and 0 (2016) shares authorized: 2% Series A Convertible Stock shares authorized 2,000,000 (2017) and 0 (2016) shares issued and outstanding 0 (2017 and 2016) 0% Series B Convertible Stock shares authorized 1,750,001 (2017) and 0 (2016) shares issued and outstanding 1,458,001 (2017) and 0 (2016)
0% Convertible Preferred Stock Series B [Member]
Stockholders' equity (Notes 7, 8 and 13):
Preferred Stock, no par value, 15,000,000 (2017) and 0 (2016) shares authorized: 2% Series A Convertible Stock shares authorized 2,000,000 (2017) and 0 (2016) shares issued and outstanding 0 (2017 and 2016) 0% Series B Convertible Stock shares authorized 1,750,001 (2017) and 0 (2016) shares issued and outstanding 1,458,001 (2017) and 0 (2016)	$ 7,745,266

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value
Preferred stock, shares authorized	15,000,000	0
Common stock, par value
Common stock, shares authorized	170,000,000	60,000,000
Common stock, shares issued	11,622,112	4,503,971
2% Convertible Preferred Stock Series A [Member]
Preferred stock, shares authorized	2,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
0% Convertible Preferred Stock Series B [Member]
Preferred stock, shares authorized	1,750,001	0
Preferred stock, shares issued	1,458,001	0
Preferred stock, shares outstanding	1,458,001	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues - Crypto-currency mining	$ 172,959
Other revenue - fee (Note 9)	96,698	96,699
Costs and expenses:
Cost of revenues (exclusive of depreciation and amortization shown below)	25,186
Selling, general and administrative (Note 8)	7,293,593	4,411,327
Research and development	20,033	249,164
Depreciation and amortization (Notes 3 and 5)	890,889	628,572
Impairment expense (Note 2)	5,218,004
Change in fair value of digital currency (gain) (Note 1)	(27,205)
Total costs and expenses	13,420,500	5,289,063
Operating loss from continuing operations	(13,150,843)	(5,192,364)
Other (expense) income:
Interest expense (Notes 6 and 7)	(4,806,637)	(30,161)
Gain (loss) on sale of property and equipment (Note 3)	(3,639)	1,942,980
Warrant inducement expense (Note 7)	(173,867)
Investment income (Note 1)	99,255	121,724
Other expenses	(1,237)
Total other income (expense)	(4,886,125)	2,034,543
Loss from continuing operations before income tax benefit	(18,036,968)	(3,157,821)
Deferred income tax benefit (Note 11)	1,609,000
Loss from continuing operations	(16,427,968)	(3,157,821)
Discontinued operations (Note 10):
(Loss) from operations	(923,645)	(1,115,016)
Escrow forfeiture gain (Note 7)	134,812
Impairment (loss) (Note 10)	(2,754,131)
Loss from discontinued operations	(3,542,964)	(1,115,016)
Net loss	(19,970,932)	(4,272,837)
Net loss attributable to non-controlling interest (Note 2)	125,059
Net loss attributable to Riot Blockchain	$ (19,845,873)	$ (4,272,837)
Basic and diluted net (loss) per share (Note 1):
Continuing operations attributable to Riot Blockchain	$ (2.71)	$ (0.78)
Discontinued operations attributable to Riot Blockchain	(0.59)	(0.27)
Net Loss	$ (3.30)	$ (1.05)
Basic and diluted weighted average number of shares outstanding (Note 1)	6,019,817	4,065,406
Amounts attributable to Riot Blockchain shareholders:
Continuing operations	$ (16,302,909)	$ (3,157,821)
Discontinued operations	(3,542,964)	(1,115,016)
Net loss attributable to Riot Blockchain	$ (19,845,873)	$ (4,272,837)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Accumulated Deficit [Member]	Total
BALANCE at Dec. 31, 2015		$ 121,653,075	$ (105,582,439)	$ 16,070,636
BALANCE, shares at Dec. 31, 2015		3,876,961
Discount on Convertible Debt arising from values of (Note 7):
Common stock issued for acquisition (Note 2 and 7)		$ 2,577,011		2,577,011
Common stock issued for acquisition (Note 2 and 7), shares		627,010
Common stock issued for services (Note 7)
Stock-based compensation issued for services (Note 8)		$ 545,549		545,549
Net loss for the year			(4,272,837)	(4,272,837)
BALANCE at Dec. 31, 2016		$ 124,775,635	(109,855,276)	14,920,359
BALANCE, shares at Dec. 31, 2016		4,503,971
Private placement of Common Stock (Note 7)		$ 1,913,509		1,913,509
Private placement of Common Stock (Note 7), shares		900,000
Common Shares in escrow forfeited and retired (Note 7)		$ (134,812)		(134,812)
Common Shares in escrow forfeited and retired (Note 7), shares		(32,801)
Equity rights redemption (Note 7)		$ (392,007)		(392,007)
Equity rights redemption (Note 7), shares
Discount on Convertible Debt arising from values of (Note 7):
Warrants		$ 2,325,151		2,325,151
Beneficial conversion feature		2,424,849		2,424,849
Preferred Stock issued upon Notes payable conversion (Note 7)	$ 4,798,671			4,798,671
Preferred Stock issued upon Notes payable conversion (Note 7), shares	19,194.72
Common stock issued for acquisition (Note 2 and 7)		$ 636,750		636,750
Common stock issued for acquisition (Note 2 and 7), shares		75,000
Cash dividend paid (Note 7)			(9,562,331)	(9,562,331)
Preferred stock issued for acquisition (Notes 2 and 7)	$ 9,296,443			8,296,443
Preferred stock issued for acquisition, shares (Notes 2 and 7)	1,750,001
Exercise of common stock purchase warrants (Note 7)		$ 1,860,000		1,860,000
Exercise of common stock purchase warrants, shares (Note 7)		620,000
Value of inducement upon temporary price reduction of common stock purchase warrants (Note 7)		$ 173,867		173,867
Cashless exercise of common stock purchase warrants (Note 7)
Cashless exercise of common stock purchase warrants, shares (Note 7)		1,335,408
Preferred stock converted to Common stock (Notes 7)	$ (6,349,848)	$ 6,349,848
Preferred stock converted to Common stock, shares (Notes 7)	(311,194.72)	2,211,472
Exercise of stock options (Note 8)		$ 149,136		149,136
Exercise of stock options (Note 8), shares		50,800
Private placement of Common Stock (Note 7)		$ 36,537,543		36,537,543
Private placement of Common Stock, shares (Note 7)		1,646,113
Common stock issued for services (Note 7)		$ 1,178,237		1,178,237
Common stock issued for services, Shares (Note 7)		138,067
Stock-based compensation issued for services (Note 8)		$ 2,589,812		2,589,812
Stock-based compensation issued for services (Note 8), shares		174,082
Net loss for the year			(19,845,873)	(19,845,873)
BALANCE at Dec. 31, 2017	$ 7,745,266	$ 180,387,518	$ (139,263,480)	$ 48,869,304
BALANCE, shares at Dec. 31, 2017	1,458,001	11,622,112

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Continuing operations:
Net loss	$ (19,970,932)	$ (4,272,837)
(Loss) from discontinued operations	(3,542,964)	(1,115,016)
Loss from continuing operations	(16,427,968)	(3,157,821)
Adjustments to reconcile net (loss) income from continuing operations to net cash used in operating activities of continuing operations:
Stock-based compensation for services	2,589,812	545,549
Depreciation and amortization	890,889	93,315
Deferred income tax benefit	(1,609,000)
Amortization of license fees	(96,698)	(96,699)
Amortization of discount on debt	4,750,000
Common stock issued for services	1,178,237
Inducement expense on warrant exercises	173,867
Asset impairment charges	5,218,004	535,256
Loss (gain) on sale of property and equipment	3,639	(1,942,980)
Change in:
Prepaid expenses and other current assets	(41,386)	309,928
Digital currencies	(200,164)
Accounts payable	90,022	(447,247)
Accrued compensation	86,264	(448,353)
Accrued expenses	(126,905)	161,604
Net cash (used in) operating activities of continuing operations	(3,521,387)	(4,447,448)
Net cash (used in) operating activities of discontinued operations	(918,663)	(1,072,296)
Net cash (used in) operating activities	(4,440,050)	(5,519,744)
Continuing operations:
Purchases of short-term investments		(16,875,550)
Proceeds from sales of short-term investments	7,506,761	24,488,780
Purchases of other investments	(3,200,000)
Proceeds from sale of property and equipment		1,808,787
Purchases of patent and trademark application costs	(61,094)	(26,067)
Cash acquired in purchase of subsidiaries	1,329,324
Acquisition of minority interest		(28,800)
Net cash provided by investing activities of continuing operations	5,574,991	9,367,150
Net cash (used in) investing activities of discontinued operations	4,004	(18,729)
Net cash provided by investing activities	5,578,995	9,348,421
Continuing operations:
Net proceeds from issuance of convertible notes	4,750,000
Repayment of notes payable and other obligations	(272,678)	(311,112)
Net proceeds from issuance of common stock	38,451,052
Payment of special cash dividend	(9,562,331)
Proceeds from exercise of warrants	1,860,000
Proceeds from exercise of stock options	149,136
Payments for redemptions of equity rights	(392,007)
Net cash provided by (used in) financing activities of continuing operations	34,983,172	(311,112)
Net increase (decrease) in cash and cash equivalents	36,122,117	3,517,565
Cash and cash equivalents at beginning of year	5,529,848	2,012,283
Cash and cash equivalents at end of year	41,651,965	5,529,848
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	5,605	35,516
Supplemental disclosure of investing information:
Liability payoffs upon property sale		2,064,758
Value of shares issued for acquisitions	9,933,193	2,577,011
Acquisitions of assets for installment obligations	$ 268,640	$ 276,640
Conversion of shares of Preferred Stock to Common Stock	6,349,848

Organization and summary of sig

Organization and summary of significant accounting policies	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and summary of significant accounting policies	Note 1. Organization and summary of significant accounting policies: Nature of operations: Riot Blockchain, Inc. (the "Company" or "Riot Blockchain") was organized on July 24, 2000, as a Colorado corporation. Effective October 19, 2017, the Company's name was changed to Riot Blockchain, Inc., from Bioptix, Inc., and as of November 30, 2016, the Company's name was changed to Bioptix, Inc., from Venaxis, Inc. Effective October 19, 2017, the Company was re-incorporated to Nevada from Colorado. On October 2, 2017 the Board of Directors of the Company approved a merger (the "Merger") of the Company with its wholly-owned subsidiary, Riot Blockchain, Inc., a Nevada corporation (the "Merger Sub"), solely for the purpose of changing the name of the Company. Upon consummation of the Merger, the separate existence of Merger Sub ceased. As permitted by Chapter 92A.180 of Nevada Revised Statutes, the purpose of the Merger was to effect a change of the Company's name to Riot Blockchain, Inc. from Bioptix, Inc. Upon approval by NASDAQ, on October 19, 2017, the Company's name was thereupon changed. The Company is building a cryptocurrency mining operation, operating specialized computers (also known as "miners") that generate cryptocurrency (primarily Bitcoin). As of December 31, 2017, the Company owned 1,200 miners acquired with the Kairos Global Technology, Inc., ("Kairos") acquisition in November 2017. During February 2018 in two separate transactions the Company acquired an additional 6,800 miners bringing the total miners owned to 8,000. During February 2018, Kairos entered into a lease agreement for approximately a 107,000-square foot facility in Oklahoma City, Oklahoma, which included data center improvements. Upon the execution of the facility lease the Company began consolidating all of its miners at the data center facility. As of March 31, 2018, 3,500 of the miners were installed and operating. Legacy Operations – Historically, the company has been an in vitro diagnostic company. The Company's business had been in the development and commercialization of innovative products that address unmet diagnostic and therapeutic needs. Until 2016, when determined that it was not prudent to use the Company's financial resources to continue to advance development of the APPY APPY APPY The Company holds an exclusive license agreement with Washington University ("WU") in St. Louis which granted the Company an exclusive license and right to sublicense its technology for veterinary products worldwide, subject to certain exceptions. In July 2012, the Company granted Ceva Sante Animale S.A. ("Ceva") an exclusive royalty-bearing license to the Company's intellectual property and other assets, relating to recombinant single chain reproductive hormone technology for use in non-human mammals. This license includes a sublicense of the technology licensed to the Company by WU. Ceva continues to advance development of the bovine rFSH product and cumulative cash payments received to date by the Company from Ceva are approximately $2 million. Through BiOptix Diagnostics, Inc., ("BDI") the Company's wholly owned subsidiary which was acquired in September 2016, the Company developed a proprietary Enhanced Surface Plasmon Resonance technology platform for the detection of molecular interactions. The Company acquired a Surface Plasma Resonance ("SPR") platform which seeks to combine high sensitivity with microarray detection capability to allow researchers to understand whether their target molecules have functionality against the disease targeted. SPR is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. Effective January 14, 2017, a plan was adopted to exit this acquired business and commenced a significant reduction in the workforce. The decision to adopt this plan was made following an evaluation by the Company's Board of Directors in January 2017, of the estimated results of operations projected during the near to mid-term period for BDI, including consideration of product development required and updated sales forecasts, and estimated additional cash resources required. See Note 10. Management's plans and basis of presentation: The Company has experienced recurring losses and negative cash flows from operations. At December 31, 2017, the Company had approximate balances of cash and cash equivalents of $41,652,000, working capital of $41,350,000, total stockholders' equity of $48,869,000 and an accumulated deficit of $139,263,000. To date, the Company has in large part relied on equity financing to fund its operations. The recently completed Kairos Global Technology, Inc. ("Kairos") and Tess, Inc., ("Tess") acquisitions and the goNumerical, Ltd. (d/b/a "Coinsquare") investment, as well as a new name, reflect a new focus (in addition to veterinary and life science oriented businesses of the Company) being pursued by the Company. The decision to invest in companies exposed to blockchain and digital currency related risks is a strategic decision by the Company. The Company's strategy will be to continue to pursue opportunistic investments and controlling positions in these new and emerging technologies which will continue to expose the Company to the numerous risks and volatility associated with this sector. Effective January 14, 2017, the Company adopted a plan to exit the business of BDI and commenced a significant reduction in the workforce. The decision to adopt this plan was made following an evaluation by the Company's Board of Directors in January 2017, of the estimated results of operations projected during the near to mid-term period for BDI, including consideration of product development required and updated sales forecasts, and estimated additional cash resources required. Accordingly, the historical results of BDI have been classified as discontinued operations for all periods presented. The Company expects to continue to incur losses from operations for the near-term and these losses could be significant as the Company incurs costs and expenses associated with the recent and potential future acquisitions and investments, as well as public company and administrative related expenses are incurred and winding-down BDI's operations. The Company believes its upcoming near-term cash needs relative to the recent acquisitions will be covered by cash acquired in the acquisitions combined with the Company's available cash. The Company believes that its current working capital position will be sufficient to meet its estimated cash needs for at least a year and a day from this filing. The Company is closely monitoring its cash balances, cash needs and expense levels. Management's strategic plans include the following: • continuing to evaluate opportunities for investments in the blockchain and digital currency sector; • exploring other possible strategic options and financing opportunities available to the Company; • evaluating options to monetize, partner or license the Company's assets, including the appendicitis product portfolio; and • continuing to implement cost control initiatives to conserve cash. Principles of consolidation The accompanying consolidated financial statements of the Company include the accounts of the Company and its wholly or majority owned and controlled subsidiaries. Consolidated subsidiaries results are included from the date the subsidiary was acquired. Intercompany investments, accounts and transactions have been eliminated in consolidation. Non–controlling interests represents the minority equity investment in the Company's subsidiaries, plus the minority investors' share of the net operating results and other components of equity relating to the non–controlling interest. The Company's consolidated subsidiaries and (percentage owned at December 31, 2017) consisted of; Kairos Global Technology, Inc., (100%) Tess, Inc., (52%) BiOptix Diagnostics, Inc., (100%). Investment in affiliate The Company's investment in Coinsquare is accounted for using the cost method. In assessing its accounting method, the Company considered guidance under ASC 323-10 and SEC Rule 3.09 relating to the percentage of ownership and the lack of factors indicating significant influence. Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company's cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. The Company invests excess cash from time to time in highly-liquid debt and equity investments of highly-rated entities, which are classified as trading securities. Such amounts are recorded at market values using Level 1 inputs in determining fair value and are generally classified as current, as the Company does not intend to hold the investments beyond twelve months. Investment securities classified as trading are those securities that are bought and held principally for the purpose of selling them in the near term, with the objective of preserving principal and generating profits. These securities are reported at fair value with unrealized gains and losses reported as an element of other (expense) income in current period earnings. As of December 31, 2017, and 2016, approximately 100% and 41%, respectively, of the investment portfolio was in cash and cash equivalents, which is presented as such on the accompanying balance sheet. For the years ended December 31, 2017 and 2016, there were approximately $16,000 and $22,000, respectively, in management fee expenses. The Company's short-term investments comprise certificates of deposit, commercial paper and corporate bonds, all of which are classified as trading securities and carried at their fair value based upon quoted market prices of the securities. Net realized and unrealized gains and losses on trading securities are included in net loss. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification. The composition of trading securities is as follows at December 31, 2017 and 2016: 2017 2016 Cost Fair Value Cost Fair Value Certificates of deposit / commercial paper $ — $ — $ 2,378,222 $ 2,373,891 Corporate bonds — — 5,138,182 5,132,870 Total trading securities $ — $ — $ 7,516,404 $ 7,506,761 Investment income for the years ended December 31, 2017 and 2016 consists of the following: 2017 2016 Interest income $ 104,886 $ 126,296 Realized gains (losses) (21 ) (3,316 ) Unrealized gains (losses) 9,893 20,641 Management fee expenses (15,503 ) (21,897 ) Net investment income $ 99,255 $ 121,724 Fair value of financial instruments: The Company accounts for financial instruments under Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic (ASC) 820, Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company's market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. There were no financial assets or liabilities measured at fair value, with the exception of cash, cash equivalents (level 1), short-term investments (level 1) digital currencies (level 1), and convertible note receivable (level 3) as of December 31, 2017 and 2016. The carrying amounts of the Company's financial instruments (other than cash, cash equivalents, short-term investments and digital currencies, as discussed above) approximate fair value because of their variable interest rates and / or short maturities combined with the recent historical interest rate levels. The Company uses Level 1 of the fair value hierarchy to measure the fair value of digital currencies and revalues its digital currencies at every reporting period and recognizes gains or losses in the consolidated statements of operations that are attributable to the change in the fair value of the digital currency. Digital currencies financial assets measured at fair value on a recurring basis are summarized below and disclosed on the December 31, 2017, balance sheets as follows: Fair value measurement using Carrying value Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 41,651,965 $ 41,651,965 $ – $ – $ 41,651,965 Digital currencies $ 200,164 $ 200,164 $ – $ – $ 200,164 Convertible note receivable $ 200,000 $ – $ – $ 200,000 $ 200,000 Segment Reporting: Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision–making group in deciding how to allocate resources and in assessing performance. Our chief operating decision–making group is composed of the chief executive officer. We currently operate in the Digital Currency Blockchain segment. Certain corporate expenses are not allocated to segment. Revenue Recognition: In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" (ASU 2014-09) as modified by ASU No. 2015-14, "Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date," ASU 2016-08, "Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing," and ASU No. 2016-12, "Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients." The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company adopted the new standard on January 1, 2018, using the modified retrospective approach. The adoption of ASU 2014-09 did not have a material impact on the Company's consolidated financial statements and related disclosures. The Company recognizes revenue when it is realized or realizable and earned. We consider revenue realized or realizable and earned when there is persuasive evidence of an arrangement and that the product has been shipped or the services have been provided to the customer, the sales price is fixed or determinable and collectability is probable. Our material revenue stream is related to the mining of digital currencies. The Company derives its revenue by providing transaction verification services within the digital currency networks of crypto-currencies, such as Bitcoin, Bitcoin Cash and Litecoin, commonly termed "crypto- currency mining." In consideration for these services, the Company receives digital currencies which are recorded as revenue, using the average U. S. dollar spot price of the related crypto-currency on the date of receipt. The coins are recorded on the balance sheet at their fair value and re–measured at each reporting date. Revaluation gains or losses, as well as gains or losses on sale of digital currencies are recorded as a component of cost of revenues in the statement of operations. Expenses associated with running the crypto-currency mining business, such as equipment deprecation, rent and electricity cost are also recorded as cost of revenues. There is currently no specific definitive guidance in U.S. GAAP or alternative accounting frameworks for the accounting for the production and mining of digital currencies and management has exercised significant judgement in determining appropriate accounting treatment for the recognition of revenue for mining of digital currencies. Management has examined various factors surrounding the substance of the Company's operations and the guidance in ASC 605, Revenue Recognition Revenue recognition related to the license agreement is based upon the licensee's right to use the technology and the Company's ongoing obligations to maintain and defend the patented rights and comply with the terms of the sub-license agreement whereby the license fees and milestone payments received from the agreement, net of the amounts due to third parties, have been recorded as deferred revenue and are amortized over the term of the license agreement. Property and equipment: Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, generally two years for crypto-currency machines and three years for computer related assets. See Note 3 for the 2016 sale of the Company's prior land and building. Patents and other intangible assets The Company accounts for intangible assets under ASC 350-30. Patents consisting of legal fees incurred are initially recorded at cost. Patents are amortized over the useful lives of the assets, using the straight-line method. Certain patents are in the legal application process and therefore are not currently being amortized. We review the carrying value of patents at the end of each reporting period. Goodwill: The Company performs a goodwill impairment analysis in the fourth quarter of each year, or whenever there is an indication of impairment. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation to determine if it is more likely than not that the fair value of its reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a two-step goodwill impairment test. The Company has determined, based on its evaluation, that the goodwill associated with the BDI acquisition was impaired and was written off during the year ended December 31, 2017, included as part of the discontinued operations impairment loss. (See Notes 2 and 10 for goodwill information). Impairment of long-lived assets: Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Based on its reviews, management determined that its crypto-currency machines where impaired by a total of $5,218,000 based upon an assessment as of December 31, 2017, including consideration of the decline in bitcoin values which occurred commencing in late December 2017 and into 2018. Certain costs previously incurred for patents were determined impaired during the year ended December 31, 2016 comprising approximately $535,000 of net patent costs, resulting from management's decisions not to pursue patents based upon a cost benefit analysis of patent expenses and coverage protection in several smaller world markets that were determined to not have the economic or fiscal potential to make the patent pursuit viable. Impairment charges are included in research and development expenses in the accompanying statements of operations. Intangible assets acquired in the Tess business combination consist primarily of in-process research and development ("IPR&D") assets. The value attributable to IPR&D projects at the time of acquisition is capitalized as an indefinite-lived intangible asset and tested for impairment until the project is completed or abandoned. Upon completion of the project, the indefinite-lived intangible asset will be accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the project is abandoned, the indefinite-lived intangible asset will be charged to expense. Research and development: Research and development costs are charged to expense as incurred. Use of estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company's financial statements include estimates associated with revenue recognition, asset valuations and useful lives in business combinations, impairment analysis of intangibles and stock-based compensation. Business Combinations: The Company accounts for acquisitions under ASC Topic 805, Business Combinations and Reorganizations When acquiring a business, the Company allocates the purchase price to the assets acquired and liabilities assumed in the transaction at their respective estimated fair values transaction costs are expensed. Any premium over the fair value of net assets acquired are recorded as goodwill. The allocation of the purchase price involves judgments and estimates both in characterizing the assets and in determining their fair value. The way the Company characterizes the assets has important implications, as long-lived assets with definitive lives, for example, are depreciated or amortized, whereas goodwill is tested annually for impairment. With respect to determining the fair value of assets, the most subjective estimates involve valuations of long-lived assets, such as property, plant, and equipment as well as identified intangible assets. The Company uses all available information to make these fair value determinations and may engage independent valuation specialists to assist in the fair value determination of the acquired long-lived assets. The fair values of long-lived assets are determined using valuation techniques that use discounted cash flow methods, independent market appraisals and other acceptable valuation techniques. Income taxes: The Company accounts for income taxes under the asset and liability method, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is required to the extent any deferred tax assets may not be realizable. ASC Topic 740, Income Taxes, ("ASC 740"), also clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company's evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company's consolidated financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position. Stock-based compensation: The Company recognizes the cost of employee services received in exchange for an award of equity instruments in the financial statements which is measured based on the grant date fair value of the award. Stock-based compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (generally the vesting period). The value of restricted stock grants are measured based on their fair market value on the date of grant and amortized over their respective vesting periods, generally twenty-four months. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Income (loss) per share ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share ("EPS") with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Basic net income (loss) per share includes no dilution and is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding for the period, including any vested but unissued restricted common shares and excluding any nonvested restricted common shares. Diluted net income (loss) per share reflect the potential dilution of securities that could share in the Company's income (loss). The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share for the years ended December 31, 2017 and 2016. Outstanding stock options, warrants, unvested restricted common shares and other dilutive rights are not considered in the calculation, as the impact of the potential common shares (totaling approximately 2,555,580 shares and 1,093,750 shares for each of the years ended December 31, 2017 and 2016, respectively) would be anti-dilutive. For the year ended December 31, 2017 the dilutive rights not considered in the calculation, include shares of Series B Convertible Preferred Stock ("Series A Preferred Stock") outstanding that are convertible into 1,458,001 common shares. For periods when shares of preferred stock are outstanding, the two-class method is used to calculate basic and diluted earnings (loss) per common share since such preferred stock is a participating security under ASC 260 Earnings per Share. The two-class method is an earnings allocation formula that determines earnings per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. Under the two-class method, basic earnings (loss) per common share is computed by dividing net earnings (loss) attributable to common share after allocation of earnings to participating securities by the weighted-average number of shares of common stock outstanding during the year. Diluted earnings (loss) per common share, when applicable, is computed using the more dilutive of the two-class method or the if-converted method. In periods of net loss, no effect is given to participating securities since they do not contractually participate in the losses of the Company. Under the provisions of ASC 260, "Earnings Per Share," basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock and the dividends accumulated for the period on cumulative preferred stock from income from continuing operations. The impact of this computation during the year ended December 31, 2017 was de minimis. Reclassification During 2017 depreciation and amortization was reclassed in the statement of operations as a separate line item. Expenses for the year ended December 31, 2016 have been reclassified to conform to the presentation. Selling, general and administrative expenses and research and development expenses for 2016 were reduced by $16,893 and $611,679, respectively, resulting in the presentation of $628,572 in depreciation and amortization expense for the year ended December 31, 2016. Depreciation and amortization expenses for 2016 included $535,256 of patent impairment charges. Recently issued and adopted accounting pronouncements: The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company's consolidated financial statements properly reflect the change. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Leases (Topic 840) Leases (Topic 842) Land Easement Practical Expedient for Transition to Topic 842 In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, the FASB issued ASU No. 2017-11, "Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815)," which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked ins

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Acquisitions	Note 2. Acquisitions: Tess Inc. Acquisition: On October 20, 2017, the Company acquired approximately 52% of Tess which is developing blockchain solutions for telecommunications companies. Under the terms of the Purchase Agreement (the "Purchase Agreement") the Company invested cash of $320,000 in Tess and issued 75,000 shares of restricted Common Stock to Tess in exchange for 2,708,333 shares of common stock of Tess. The 75,000 shares of Common Stock were valued at the $8.49 market price as of October 20, 2017 for a total of $636,750. Accordingly, Tess became a majority-owned subsidiary of the Company. As part of the transaction, the Company and Tess entered into a registration rights agreement pursuant to which the Company agreed to file a registration statement to register the resale of 25,000 shares (of 75,000 shares) of Common Stock issued to Tess. Under the acquisition method of accounting (FASB ASU 2017-01, Business Combinations (Topic 805)), the total estimated purchase consideration has been preliminarily allocated to the acquired tangible and intangible assets and assumed liabilities based on their estimated fair values as of the acquisition date. In consideration of the provisions of ASU 2017-01, the Company evaluated the status of the acquired subsidiary's assets and operations to evaluate its inputs and processes for the creation of or the ability to contribute to the creation of outputs. The evaluation included assessment of Tess' processes and prospective customer relationships that resulted in the execution of a letter of intent in early December 2017 for Tess to raise additional funds and merge with a third-party. The Company has completed a preliminary allocation of the purchase consideration. The following preliminary allocation of the purchase consideration is subject to revision as additional information becomes known in the future: Cash $ 198,000 Accounts receivable and prepaid expenses 9,000 In-process research and development 720,000 Goodwill 799,000 Accounts payable (21,000 ) Deferred income tax liability (186,000 ) Non-controlling interest (883,000 ) Purchase price $ 636,000 Intangible rights acquired consisted of the following as of December 31, 2017: In-process research and development $ 720,000 Goodwill 799,000 Total 1,519,000 Less accumulated amortization — Net acquired intangibles $ 1,519,000 The non-controlling interest represents the 48% proportionate share held by the minority shareholders of Tess. As of the acquisition the value of the 48% non-controlling interest implied from the purchase price totaled $883,000. The net loss attributable to the non-controlling interest for the period from acquisition to December 31, 2017 totaled $125,000, leaving a balance of $758,000 at December 31, 2017. Tess is developing TessPay and other blockchain on-line solutions for telecommunications companies. TessPay is a payments ecosystem for component and sub-component supply chain settlements (payments). The preliminary allocation of purchase consideration includes $720,000 as in-process research and development (IPR&D) related to the TessPay project. The valuation considered assumptions consistent with similar projects, including expectation of cash flows expected to commence in late 2018, future probable cash flows from the Tesspay project, discounted at a present value factor of approximately 60%. In January 2018, following the execution of a non-binding letter of intent as of December 11, 2017, the parties executed a definitive agreement providing that the Company's majority owned subsidiary Tess agreed to merge with Cresval Capital Corp. ("Cresval") (TSX-V: CRV). Assuming closing conditions are met, upon closing of the anticipated merger, Tess will be publicly traded on the TSX Venture Exchange (the "TSXV") and change its name to "TessPay Inc.". The agreement provides that Tess will be issued 80,000,000 shares of Cresval, and the present shareholders of Cresval will retain 8,400,000 shares of the combined company TessPay post-merger. The Company will receive 41,600,000 shares in the transaction resulting from its 52% ownership of Tess. No assurance can be given that the proposed merger will be consummated, or that the combined company will be able to obtain adequate funds needed to fund its business plan. Based upon the agreed to terms of the agreement, the Company anticipates that the merger will be accounted for as an acquisition by Tess of Cresval. The Company expects the acquisition, assuming it closes under the agreed to terms, to result in the Company owning less than 50% of Tess, at which time it would no longer be expected to be consolidated. Pro Forma Results of Operations: The unaudited supplemental pro forma information for the year ended December 31, 2017, as if the Tess acquisition had occurred as of its date of inception in 2017 were not material to the consolidated financial results as presented. Kairos Global Technology, Inc. Acquisition: On November 3, 2017, the Company closed on a business combination share exchange agreement (the "Agreement") with Kairos Global Technology, Inc., a Nevada corporation. Under the Agreement, the shareholders of Kairos agreed to exchange all outstanding shares of Kairos' common stock to the Company and the Company agreed to issue an aggregate of One Million Seven Hundred Fifty Thousand and One (1,750,001) newly-designated shares of Series B Convertible Preferred Stock (the "Series B Preferred Stock") which are convertible into an aggregate of One Million Seven Hundred Fifty Thousand and One (1,750,001) shares of the Company's common stock, no par value per share (the transaction, the "Kairos Transaction") to such shareholders. See Note 7 for further information about the Series B Preferred Stock. The 1,750,001 Series B Preferred Shares were valued at approximately $5.31 per share based upon the then value of the Company's common shares, discounted based upon restrictions associated with the preferred shares, for a total value of approximately $9,296,000. The shareholders of Kairos also will receive a royalty to be paid from cash flow generated from operations, as defined in the Agreement, which shall entitle such shareholders to receive 40% of the gross profits generated on a monthly basis until they have received a total of $1,000,000, at which point the royalty is extinguished. For financial reporting purposes the royalty liability will be recorded as the contingency is resolved and obligation determined. Kairos owned certain computer equipment and other assets used for the mining of cryptocurrency, specifically servers consisting of 700 AntMiner S9s and 500 AntMiner L3s, all manufactured by Bitmain. (See Note 13.) Under the acquisition method of accounting (FASB ASU 2017-01, Business Combinations (Topic 805)), the total estimated purchase consideration has been preliminarily allocated to the acquired mining assets based on the estimated fair value of the consideration as of the acquisition date. In consideration of the provisions of ASU 2017-01, the Company evaluated the status of the acquired subsidiary's assets and operations to evaluate its inputs and processes for the creation of or the ability to contribute to the creation of outputs. We have completed an allocation of the purchase consideration. The following is the allocation of the purchase consideration: Cash $ 1,131,000 Equipment 10,333,000 Accounts payable and accrued expenses (46,000 ) Deferred income tax liability (2,122,000 ) Purchase price $ 9,296,000 The equipment acquired is estimated to have average lives of two years, which will result in annual estimated future depreciation of approximately $2,350,000 per year following the impact of the impairment expense. Equipment rights acquired consisted of the following as of December 31, 2017 net of depreciation and impairment: Equipment $ 4,700,575 Less accumulated amortization (406,409 ) Net acquired equipment $ 4,294,166 As of December 31, 2017, the Company performed a review of its digital equipment assets based upon the significant decline in bitcoin values that occurred as of yearend. Recoverability of the digital equipment assets being held and used was measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the assets. Based upon that assessment, the assets were considered to be impaired. The $5,218,000 impairment recognized was measured by the amount by which the carrying amount of the digital assets as of December 31, 2017, exceeded the fair value of such assets. Management will review its net equipment for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Such impairment analysis may be impacted by the value of digital currencies as they are mined in the future. In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. ASU 2015-16 eliminates the requirement to restate prior period financial statements for measurement period adjustments. The new guidance requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. In addition, separate presentation on the face of the income statement or disclosure in the notes is required regarding the portion of the adjustment recorded in the current period earnings, by line item, which would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is to be applied prospectively for measurement period adjustments that occur after the effective date. ASU 2015-16 is effective for annual reporting periods beginning after December 15, 2015. The Company adopted this guidance on January 1, 2016 and the adoption thereof did not have a material impact on the Company's consolidated financial statements.

Property and equipment

Property and equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and equipment	Note 3. Property and equipment: Property and equipment consisted of the following as of December 31: 2017 2016 Crypto-currency machines $ 4,700,575 $ — Office and computer equipment 61,670 116,510 4,762,245 116,510 Less accumulated depreciation 468,079 110,972 $ 4,294,166 $ 5,538 Depreciation and amortization expense totaled approximately $891,000 and $4,000, for the years ended December 31, 2017 and 2016, respectively. Depreciation is computed on the straight-line basis for the periods the assets are in service. As of December 31, 2017 $414,581 of accumulated depreciation arising from the impairment change and $51,201 in other equipment accumulated depreciation was written-off. On February 25, 2016, the Company completed the sale of its corporate headquarters, land, building and certain fixtures and equipment to a third party for a purchase price of approximately $4,000,000. The sale resulted in a gain of approximately $1,943,000 and generated approximately $1,809,000 in net cash after expenses and mortgage payoffs. See Note 14 for equipment related transactions subsequent to December 31, 2017.

Investment in goNumerical

Investment in goNumerical	12 Months Ended
	Dec. 31, 2017
Investments, All Other Investments [Abstract]
Investment in goNumerical	Note 4. Investment in goNumerical: As of September 29, 2017, the Company acquired a minority interest for $3,000,000 USD, in goNumerical, Ltd., (d/b/a: Coinsquare), which operates a digital crypto-currency exchange platform operating in Canada. The Company acquired approximately 10.9% of the voting common stock of Coinsquare. In connection with the investment, the Company also received warrants, expiring May 30, 2018, to acquire shares of common stock of Coinsquare, which if exercised in full by the Company, would result in the Company owning an approximate total of 14.7% of Coinsquare, including the initial investment. The fair value of the warrants was determined to be de minimis. Investments – Other Subsequent to December 31, 2017, during February 2018 the Company invested an additional $6.4 million in Coinsquare. The investment included an additional equity investment of $2.8 million that is part of an approximate $24 million financing by Coinsquare. Additionally, warrants acquired in the original investment were exercised in exchange of a cash payment of $3.6 million. These additional investments resulted in a current ownership in Coinsquare by the Company of approximately 12.9% based upon Coinsquare's issued and outstanding shares.

Other long-term assets

Other long-term assets	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Other long-term assets	Note 5. Other long-term assets: Other long-term assets consisted of the following as of December 31, 2017 and December 31, 2016: Beginning Balance Additions Impairments Ending Balance Year ended December 31, 2017: Cost: Patents $ 1,032,982 $ 26,850 $ — $ 1,059,832 Goodwill 447,951 799,257 — 1,247,208 Convertible Note Investment — 200,000 — 200,000 Total 1,480,933 1,026,107 — 2,507,040 Accumulated Amortization: Patents (482,183 ) (68,000 ) — (550,183 ) Goodwill (60,712 ) — — (60,712 ) Total (542,895 ) (68,000 ) — (610,895 ) Net Other Long-term Assets $ 938,038 $ 958,107 $ — $ 1,896,145 Year ended December 31, 2016: Cost: Patents $ 1,684,737 $ 26,067 $ (677,822 ) $ 1,032,982 Goodwill 447,951 — — 447,951 Total 2,132,688 26,067 (677,822 ) 1,480,933 Accumulated Amortization: Patents (548,327 ) (76,422 ) 142,566 (482,183 ) Goodwill (60,712 ) — — (60,712 ) Total (609,039 ) (76,422 ) 142,566 (542,895 ) Net Other Long-term Assets $ 1,523,649 $ (50,355 ) $ (535,256 ) $ 938,038 The Company capitalizes legal costs and filing fees associated with obtaining patents on its new discoveries. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. Amortization expense totaled $68,000 and $76,000 for the years ended December 31, 2017 and 2016, respectively. Based upon the current status of the above intangible assets, the aggregate amortization expense is estimated to be approximately $60,000 for each of the next five fiscal years. The Company tests intangible assets with finite lives upon significant changes in the Company's business environment. The testing resulted in approximately $0 and $535,000 of net patent impairment charges during the years ended December 31, 2017 and 2016, respectively. The impairment charges are related to the Company's ongoing analysis on which specific patents in specific countries the Company intends to continue to pursue. During November 2017, the Company made a $200,000 investment in a convertible note as part of a series of notes issued and being issued by Verady, LLC ("Verady"). The notes are unsecured, subordinated to other approved liabilities, mature December 31, 2022, bear interest at 6%, unless previously repaid or converted and contain other conditions and restrictions, all as defined under the subscription documents. The Verady convertible note is recorded at fair value using level 3 valuation criteria. As of December 31, 2017, the Company considers fair value to equal cost. The conversion rate of the convertible note is defined based upon the possible occurrence of certain defined events which may or may not occur. If such a defined event successfully occurs, the Company currently estimates that its convertible note would result in a maximum ownership interest of approximately 12%. The Company has no other relationship or rights associated with Verady. Founded in 2016, Verady is privately held and recently launched VeraNet, a decentralized network of financial reporting and accounting tools targeted to the needs of the cryptocurrency community.

Notes and other obligations

Notes and other obligations	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes and other obligations	Note 6. Notes and other obligations: Notes and other obligations consisted of short-term installment obligations, arising from insurance premium financing programs bearing interest at approximately 4.5%, with outstanding balances of $135,574 and $139,611, as of December 31, 2017 and 2016, respectively. Convertible notes: In March 2017, the Company completed a convertible note financing with certain accredited investors with gross proceeds totaling $4,750,000. The convertible notes bearing interest at 2% were issued March 16, 2017 and had a balloon payment maturity date of September 16, 2018, when any then outstanding principal and accrued interest, would be due. The unsecured notes were convertible into shares of the Company's common stock at the holder's option or automatically into shares of preferred stock, upon achievement of defined conditions, including shareholder approval of a class of preferred stock, all at an initial conversion price of $2.50 (initially 1,900,000 common shares). In connection with the financing investors were issued warrants exercisable into a total of 1,900,000 common shares at an exercise price of $3.56, expiring March 15, 2020. The convertible note financing proceeds were held in escrow pending successful completion of defined release conditions. As of August 18, 2017, the lead investor in the convertible note financing, agreed to waive the release conditions and the cash proceeds and securities were released from escrow. As of September 20, 2017, upon the successful completion of conditions specified in the offering documents, and as further described in Note 7, the notes automatically converted into shares of Series A Preferred Stock. The convertible notes accrued interest at 2% per annum commencing with their execution and the Company recorded interest expense of $48,671 through the date of conversion, which was also exchanged for shares of Series A Preferred Stock. See Note 7. Mortgage notes: Prior to the February 2016 sale of the corporate headquarters, the Company had a permanent mortgage on its land and building. The mortgage was held by a commercial bank and included a portion guaranteed by the U. S. Small Business Administration ("SBA"). The loan was collateralized by the real property and the SBA portion was also personally guaranteed by a former officer of the Company. The commercial bank loan terms included a payment schedule based on a fifteen-year amortization, with a balloon maturity at five years. The commercial bank portion had an interest rate fixed at 3.95%, and the SBA portion bore interest at the rate of 5.86%. On February 25, 2016, the Company completed the sale of its corporate headquarters, land and building, and also paid off its mortgage obligations. See Note 3.

Stockholders' equity

Stockholders' equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' equity	Note 7. Stockholders' equity: Articles of Incorporation amendments: Effective September 19, 2017, the Company changed its state of incorporation from Colorado to Nevada (the "Reincorporation"). In connection with the Reincorporation and as approved by the Company's shareholders at a special meeting held August 21, 2017 Special Shareholders' Meeting, the Company's Articles of Incorporation were amended to increase the number of shares of common stock authorized for issuance to 170,000,000 from 60,000,000. Additionally, the Articles of Incorporation were amended to authorize 15,000,000 shares of "blank check" preferred stock. Preferred Stock: Series A – Preferred Stock On September 20, 2017, 2,000,000 shares of preferred stock were designated as "2% Series A Convertible Preferred Stock" in connection with the filing of a Certificate of Designation of Rights, Powers, Preferences, Privileges and Restrictions of 2% Series A Convertible Preferred Stock with the Secretary of State of the State of Nevada. The Series A Preferred Stock are convertible into shares of common stock based on a conversion calculation equal to the stated value ($250.00 per share) of such shares of Series A Preferred Stock, plus all accrued and unpaid dividends, if any, on such shares of Series A Preferred Stock, divided by the conversion price of $2.50, subject to adjustments. The shares of Series A Preferred Stock are subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. Shares of capital stock of the Company shall be junior in rank to all shares of Series A Preferred Stock with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding-up of the Company. Each holder of shares of Series A Preferred Stock shall be entitled to receive dividends, which dividends shall be paid by the Company out of funds legally available therefor, payable, subject to the conditions and other terms hereof, in shares of common stock or cash on the stated value of such shares of Series A Preferred Stock at the dividend rate of two percent (2%) per annum, which shall be cumulative and shall continue to accrue and compound monthly whether or not declared. Holders of shares of Series A Preferred Stock, shall be entitled to vote on any proposals voted on by the common shareholders. In March 2017, the Company completed a 2% convertible note financing with certain accredited investors with gross proceeds totaling $4,750,000 (see Note 6). As of September 20, 2017, upon the successful completion of conditions specified in the offering documents, primarily approval by the Company's shareholders for authorization of preferred shares and approval of the Nasdaq Capital Market ("NASDAQ"), the notes automatically converted into shares of Series A Preferred Stock, at an equivalent conversion price of $2.50 per common share, resulting in the conversion of $4,750,000 in principal and accrued interest of $48,671 for a total of $4,798,671 worth of convertible notes, exchanged for 19,194.72 shares of Series A Preferred Stock, with a stated value of $250 per share, equaling rights to 1,919,472 shares of common stock. The convertible notes accrued interest at 2% per annum commencing with their execution and the Company recorded interest expense of $48,671 through the date of conversion of the notes. Subsequent to the September 20, 2017 issuance of the Series A Preferred Stock, the holders of the 19,194.72 Series A Preferred Shares elected to exchange those shares for 1,919,472 shares of the Company's Common Stock as provided in the agreements. As of December 31, 2017, all outstanding shares of Series A Preferred Stock had been converted to shares of Common Stock. Series B – Preferred Stock On November 3, 2017, the Company designated 1,750,001 shares of preferred stock as "0% Series B Convertible Preferred Stock" in connection with the filing of the Certificate of Designation with the Secretary of State of the State of Nevada. Pursuant to the Kairos share exchange agreement which closed as of November 3, 2017, the shareholders of Kairos agreed to exchange all outstanding shares of Kairos' common stock to the Company and the Company agreed to issue an aggregate of One Million Seven Hundred Fifty Thousand and One (1,750,001) newly designated shares of Series B Convertible Preferred Stock (the "Series B Preferred Stock") which are convertible into an aggregate of One Million Seven Hundred Fifty Thousand and One (1,750,001) shares of the Company's common stock, no par value per share to such shareholders. The shares of Series B Preferred Stock are convertible into shares of common stock based on a conversion calculation equal to the stated value of the Series B Preferred Stock, plus all accrued and unpaid dividends, if any, on such Series B Preferred Stock, as of such date of determination, divided by the conversion price. The stated value of each share of Series B Preferred Stock is $6.80 and the initial conversion price is $6.80 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. The holders of Series B Preferred Stock are entitled to receive dividends if and when declared by the Company's board of directors. The Series B Preferred Stock will participate on an "as converted" basis, with all dividends declared on the Company's common stock. Such dividends will be paid by the Company out of funds legally available therefor, payable, subject to the conditions and other terms hereof, in cash on the stated value of such Series B Preferred Stock. The Company is prohibited from effecting a conversion of the Series B Preferred Stock to the extent that, as a result of such conversion, the holder would beneficially own more than 4.99% percent of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the Series B Preferred Stock, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99% percent. Each holder is entitled to vote on all matters submitted to stockholders of the Company, and will have the number of votes equal to the number of shares of common stock issuable upon conversion of such holder's Series B Preferred Stock. The Series B Preferred Stock contains a blocker pursuant to which, if the Company has not obtained the approval of its shareholders in accordance with NASDAQ Listing Rule 5635(d), then the Company may not issue upon conversion of the Series B Preferred Stock a number of shares of common stock, which, when aggregated with any other shares of common stock underlying the Series B Preferred Stock issued pursuant to the Agreement would exceed 19.99% of the shares of common stock issued and outstanding as of the date of the Agreement, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the common stock that occur after the date of the Agreement. On December 21, 2017, the Company amended the Certificate of Designation of Rights, Powers, Preferences, Privileges and Restrictions of 0% Series B Convertible Preferred Stock (the "Amendment") in order to remove the voting rights of the Series B Preferred Stock. Subsequent to the November 3, 2017 issuance of the Series B Preferred Stock, holders of 292,000 Series B Preferred Shares elected to convert those shares for 292,000 shares of the Company's Common Stock as provided in the agreements. As of December 31, 2017, 1,458,001 shares of Series B Preferred Stock were outstanding. Following is a summary of Series A and Series B Preferred Stock activity for the year ended December 31, 2017: Series A Series B Total Preferred Stock Shares Amount Shares Amount Shares Amount Balance, January 1, 2017 — $ — — $ — $ — $ — Preferred stock issued upon notes payable conversion 19,194.72 4,798,671 — — 19,194.72 4,798,671 Preferred stock issued for Kairos acquisition 1,750,001.00 9,296,443 1,750,001.00 9,296,443 Series A Preferred stock converted to Common stock (19,194.72 ) (4,798,671 ) — — (19,194.72 ) (4,798,671 ) Series B Preferred stock converted to Common stock — — (292,000.00 ) (1,551,177 ) (292,000.00 ) (1,551,177 ) Balance, December 31, 2017 — $ — 1,458,001.00 $ 7,745,266 $ 1,458,001.00 $ 7,745,266 Subsequent to December 31, 2017, holder of 619,518 Series B Preferred Shares elected to convert those shares for 619,518 share's of the Company's Common Stock. Common Stock: 2017 Transactions: Common Share Private Placement offering: In March 2017, the Company completed a common stock unit financing private placement totaling $2,250,000, with certain accredited investors. The purchase price was $2.50 per unit (the "Units"). Each Unit consisted of one share of the Company's common stock and a three-year warrant to purchase one share of the Company's common stock at an exercise price of $3.50 per share. The fair value of the 900,000 warrants was estimated to be approximately $2,114,000, using the Black-Scholes option-pricing model using the assumptions of a three-year term, expected price volatility of 114%, dividend yield of 0% and a risk-free interest rate of 1.66%. The Company sold 900,000 units consisting of an aggregate of 900,000 shares of common stock and 900,000 warrants, of which 400,000 units for $1,000,000 were released to the respective parties in March 2017, and the balance of 500,000 units for $1,250,000 were released in May 2017. The offering net of $336,491 of offering expenses, resulted in proceeds of $1,913,509 recorded as additional equity. In connection with the private placement, the Company also entered into a Registration Rights Agreement, with the investors. On December 21, 2017, investors holding a majority of the outstanding securities registrable pursuant to the agreement, agreed on behalf of all investors to waive the requirement for the filing of a registration statement and terminate the registration rights agreements. The investors further waived any and all damages, penalties and defaults related to the Company's not filing the registration statement by the filing date and any damages, penalties and defaults related to the Company not having a registration statement be declared effective by the specified date (as such terms are originally defined in the Unit Registration Rights Agreement). Common stock escrow forfeiture: During the year ended December 31, 2017, under an agreement between the Company and one of the selling shareholders from the Company's 2016 acquisition of BDI, rights to 32,801 common shares held in escrow on behalf of the selling shareholder were waived by the shareholder and returned to the Company where they were cancelled. Under the agreement each party mutually released each other from any and all claims that might relate to or arise from the acquisition of BDI. As a result of this cancellation, $134,812, which was the estimated fair market value of the 32,801 common shares, based upon $4.11 per share, was recorded as a gain in the BDI discontinued operations and a reduction in common stock. The Company considered ASC 805-20-25-27 accounting for indemnification assets at closing of the BDI acquisition and at subsequent reporting periods and determined that no value for the shares held in escrow was recordable, until the settlement agreement was agreed to. Equity rights termination redemptions: During the year ended December 31, 2017, the Company negotiated and executed agreements with holders of stock rights (stock options and restricted shares) to have such holders waive their rights to the stock rights in exchange for a one-time cash payment. The majority of the holders had previously terminated from the Company or the agreements were made as part of separation agreements upon the individuals' termination from the Company. Under the agreements, a total of 553,911 rights were forfeited, consisting of; 515,578 stock options under the Company's 2002 Stock Incentive Plan (the "2002 Plan"), 37,500 non-qualified options issued outside of the 2002 Plan and 833 restricted common shares. The total consideration under the agreements was $399,513. For financial reporting purposes the amounts paid to each holder was compared to the fair value of the stock rights forfeited using a Black-Scholes valuation and to the extent the amount paid exceeded the value of the stock rights forfeited, the payment amount was charged to stock-based compensation. For purposes of the Black-Scholes valuation, the Company assumed a dividend yield of 0%, expected price volatility of 49% to 99% risk free interest rates of 0.8% to 2.3% and expected terms based upon the remaining lives of the instruments. Of the total amount paid, $392,007 was charged to stockholders' equity and $7,506 was charged to compensation expense. Convertible Note Private Placement offering: In March 2017, the Company completed a 2% convertible note financing with certain accredited investors with gross proceeds totaling $4,750,000. The convertible note financing proceeds were held in escrow pending successful completion of defined release conditions. As of August 18, 2017, the lead investor in the convertible note financing, agreed to waive the release conditions and the cash proceeds and securities were released from escrow. Upon the successful completion of conditions specified in the offering documents, primarily approval by the Company's shareholders for authorization of preferred shares and approval of the Nasdaq Capital Market ("NASDAQ"), the notes automatically converted into shares of Series A Preferred Stock, convertible into shares of common stock at an initial equivalent conversion price of $2.50 per common share. The specified conditions were successfully completed as of September 20, 2017, resulting in the conversion of $4,750,000 in principal and accrued interest of $48,671 for a total of $4,798,671 worth of convertible notes, exchanged for 19,194.72 shares of Series A Preferred Stock, with a stated value of $250 per share, equaling rights to 1,919,472 shares of common stock. The convertible notes accrued interest at 2% per annum commencing with their execution and the Company recorded interest expense of $48,671 through the date of conversion of the notes. Warrants to purchase 1,900,000 shares of the Company's common stock at an initial exercise price of $3.56 per share and expiring March 15, 2020, were also issued with the convertible note financing. The Company has evaluated the guidance ASC 480-10 Distinguishing Liabilities from Equity, A Contracts in an Entity's Own Equity Debt with Conversion and Other Options In connection with the private placement, the Company also entered into a Registration Rights Agreement, with the investors. On December 21, 2017, investors holding a majority of the outstanding securities registrable pursuant to the agreement, agreed on behalf of all investors to waive the requirement for the filing of a registration statement and terminate the registration rights agreements. The investors further waived any and all damages, penalties and defaults related to the Company's not filing the registration statement by the filing date and any damages, penalties and defaults related to the Company not having a registration statement be declared effective by the specified date (as such terms are originally defined in the Unit Registration Rights Agreement). Common Stock issued for Acquisition: On October 20, 2017, the Company issued 75,000 shares of Common Stock in connection with the majority acquisition of Tess. The issuance of the shares was completed as a private placement transaction. In connection with the transaction, the Company and Tess entered into a Registration Rights Agreement pursuant to which the Company agreed to file a registration statement within three months to register the resale of 25,000 shares (of 75,000 shares) of Common Stock issued to Tess. Cash Dividend: On October 2, 2017, the Company's Board of Directors approved a cash dividend pursuant to which the holders of the Company's common stock and Series A Preferred Stock, would receive $1.00 for each share of Common Stock held, including each share of Common Stock that would be issuable upon conversion of the Series A Preferred Stock, on an as converted basis. The cash dividend, accounted for as a return of capital, totaled approximately $9,562,000 with a record date of the close of business on October 13, 2017 and payment date of October 18, 2017. Temporary Reduction in Warrant Exercise Prices: On October 10, 2017, the Company's Board of Directors approved a temporary reduction in the exercise price of warrants issued in the March 2017 private offerings to $3.00 per share. The approval covered any of the 2,800,000 outstanding warrants which would be exercised by their holders from October 10, 2017 through October 20, 2017, for cash. During that period 620,000 warrants were exercised for cash, resulting in $1,860,000 in proceeds to the Company. Any such warrant holder who exercised such warrants for cash at the reduced price shall not be entitled to the benefit of any cashless exercise feature on such exercised warrants. The fair value of the temporary modification of the reducing the exercise price was recorded as an additional expense and a credit to capital in the period of exercise. The fair value was computed to be $173,867, based upon the increase in fair value of the warrants immediately before and immediately after the reduction in exercise price times the 620,000 warrants actually exercised. Cashless Exercise of Common Stock Purchase Warrants: During the year ended December 31, 2017, warrant holders of 2,244,147 common share rights elected to exercise their warrants on a net cashless basis and were issued a net of 1,335,408 shares of common stock in exchange for termination of the warrants. Warrants issued in the May 2013 private offering at an exercise price of $10.88 per common share for 184,147 share rights were surrendered for the issuance of 106,719 common shares. Warrants issued in the March 2017 private offering of common stock at an exercise price of $3.50 per common share for 360,000 share rights were surrendered for the issuance of 214,851 common shares. Warrants issued in the Mach 2017 private offering of convertible notes at an exercise price of $3.56 per common share for 1,700,000 share rights were surrendered for the issuance of 1,013,838 common shares. The Company evaluated the provisions of ASC 815 Derivatives and Hedging regarding the accounting for these cashless warrant exercises. Based upon the fact that no changes were made to the terms of the warrants following their issuance and the exceptions to derivative instruments under ASC 815-15-74 for contracts issued by the reporting entity that are indexed in the entity's own stock and classified in stockholders' equity, it was determined that no expense recognition is required. Restricted Common Stock Awards: During the year ended December 31, 2017, 863,000 restricted shares were granted to directors and officers under the Company's equity incentive plans, of which 40,000 were terminated upon the individuals' separation from the Company. As of December 31, 2017, 326,848 restricted common shares had vested and 174,082 had been issued. See Note 8. During the year ended December 31, 2017, the Company issued 138,067 restricted common shares to consultants for services recorded at a value of approximately $1,178,200. Subsequent to December 31, 2107, 3,215 restricted common shares were issued to a consultant. Common Share Private Placement offering: On December 21, 2017, the Company closed on the sale of approximately $36,537,543 of units, net of approximately $500,000 in offering expenses of its securities and issued 1,646,113 shares of Common Stock and warrants to purchase up to 1,646,113 shares of Common Stock (the "Units") pursuant to separate purchase agreements (the "Securities Purchase Agreements") with accredited investors (the "Investors"), at a purchase price of $22.50 per Unit. Each Unit consists of one share (the "Shares") of the Company's common stock, no par value per share (the "Common Stock"), and a three-year warrant (the "Warrants") to purchase one share of Common Stock, at an exercise price of $40.00 per share (such sale and issuance, the "Private Placement"). The closing of the Private Placement is subject to customary closing conditions. The Warrants are exercisable, at any time on or after the sixth month anniversary of the closing date of the Private Placement, at a price of $40.00 per share, subject to adjustment, and expire three years therefrom. The holders may, subject to certain limitations, exercise the Warrants on a cashless basis. The Company is prohibited from effecting an exercise of any Warrant to the extent that, as a result of any such exercise, the holder would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of such Warrant. The Company entered into separate registration rights agreements (the "Registration Rights Agreement") with each of the Investors, pursuant to which the Company will undertake to file a registration statement to register the Common Stock issued as part of the Units and the Common Stock issuable upon exercise of the Warrants, within fourteen days following the closing, to cause such registration statement to be declared effective by the Securities and Exchange Commission within ninety days of the filing date and to maintain the effectiveness of the registration statement until all of such shares of Common Stock registered have been sold or are otherwise able to be sold pursuant to Rule 144. In the event the Company fails to file, or obtain effectiveness of, such registration statement with the given period of time, the Company will be obligated to pay liquidated damages to the Investors for every thirty-days during which such filing is not made and/or effectiveness obtained, such fee being subject to certain exceptions. 2016 Transactions: On September 12, 2016, the Company issued an aggregate of 627,010 shares of common stock of the Company as consideration for the acquisition of the Preferred Stock of BDI, thereby making BDI a majority-owned subsidiary of the Company. The issuance of the shares was effected as a private placement transaction. See Note 2. Upon the completion of a special shareholders meeting on March 24, 2016, where such action was approved by shareholders, the Board of Directors authorized the Reverse Stock Split at a ratio of one-for-eight, whereby each eight shares of common stock were combined into one share of common stock. The Reverse Stock Split was implemented and effective on March 31, 2016. All historical references to shares and share amounts in this report have been retroactively revised to reflect the Reverse Stock Split. Subsequent Stockholders' Equity transactions: See Notes 8 and 14 for stockholders' equity transactions subsequent to December 31, 2017.

Stock options and warrants

Stock options and warrants	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock options and warrants	Note 8. Stock options and warrants: The Company currently provides stock-based compensation to employees, directors and consultants, both under the Company's 2017 Equity Incentive Plan, as approved by the Company's shareholders on August 21, 2017 (the "Plan") and non-qualified options and warrants issued outside of the Plan. The Company's previous 2002 Stock Incentive Plan, as amended was replaced by the 2017 Plan with the 2002 Stock Incentive Plan continuing to govern the then outstanding grants and awards for 91,333 options and 157,000 shares of restricted common stock, but no additional grants are to be made. The 2017 Plan was approved reserving 895,000 common shares under the Plan. The Company estimates the fair value of the share-based awards on the date of grant using the Black-Scholes option-pricing model (the "Black-Scholes model"). Using the Black-Scholes model, the value of the award that is ultimately expected to vest is recognized over the requisite service period in the statement of operations. Option forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company attributes compensation to expense using the straight-line single option method for all options granted. The Company's determination of the estimated fair value of share-based payment awards on the date of grant is affected by the following variables and assumptions: · The grant date exercise price – the closing market price of the Company's common stock on the date of the grant; · Expected option term – based on historical experience with existing option holders estimated at 3-5 years; · Estimated dividend rates – based on historical and anticipated dividends over the life of the option; · Term of the option – grants have lives of 10 years; · Risk-free interest rates – with maturities that approximate the expected life of the options granted; · Calculated stock price volatility – calculated over the expected life of the options granted, which is calculated based on the daily closing price of the Company's common stock over a period equal to the expected term of the option; and · Option exercise behaviors – based on actual and projected employee stock option exercises and forfeitures. The Company recognized stock-based compensation totaling $2,589,812 and $545,549 during the years ended December 31, 2017 and 2016, respectively. The total expense for the year ended December 31, 2017, consisted of $1,714,116 in expense for the issuance of restricted common shares, $767,675 for the issuance of stock options under the Plan and $108,021 from other options. These expenses are included in the accompanying Statements of Operations for the years ended December 31, in the following categories: 2017 2016 Selling, general and administrative expenses $ 2,589,812 $ 542,989 Research and development expenses — 2,560 Total stock-based compensation $ 2,589,812 $ 545,549 Restricted stock awards: A summary of the Company's restricted stock activity in the year ended December 31, 2017 is presented here: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2017 - $ - Granted 863,000 5.39 Vested (326,848 ) 4.79 Forfeited (40,000 ) 3.13 Unvested at December 31, 2017 496,152 $ 5.97 During the year ended December 31, 2017, the Company granted 863,000 restricted shares to members of its Board of Directors, Advisory Board members and officers. As of December 31, 2017, of the 326,848 restricted shares which had vested, 174,082 had been issued with 152,766 vested rights remaining to be issued. Upon the separation of two Directors, 40,000 restricted shares were subsequently forfeited, including 833 restricted shares that were re-acquired by the Company as part of the equity rights terminations (see Note 7). The weighted-average grant date fair value of restricted shares granted during the year ended December 31, 2017 was $5.39 per share based upon the share price as of the date of grant. The total fair value of restricted stock granted, net of approximately $125,000 of forfeitures, during the year ended December 31, 2017 was approximately $4,654,000, including approximately $1,565,000 which vested in the period. The value of restricted stock grants are measured based on their fair market value on the date of grant and amortized over their respective vesting periods, generally twenty-four months. As of December 31, 2017, there was approximately $2,964,000 of unrecognized compensation cost related to unvested restricted stock awards, which is expected to be recognized over a remaining weighted-average vesting period of approximately 1.0 years. Subsequent to December 31, 2017 a total of 292,500 shares of restricted common stock subject to vesting and acceleration provisions were granted to certain board members and officers. Upon the resignation of a member of the Company's Board of Directors and an Advisory Board member, 6,251 and 20,000, respectively of previously awarded restricted shares were forfeited. In March 2018, 50,000 vested restricted common shares were issued. Stock incentive plan options: The Company currently provides stock-based compensation to employees, directors and consultants under the Plan. The Company utilized assumptions in the estimation of fair value of stock-based compensation for the years ended December 31, as follows: 2017 2016 Dividend yield 0 % 0 % Expected price volatility 95 to 15 % 99 to 100 % Risk free interest rate 1.92 to 1.99 % 1.20 to 1.83 % Expected term 5 years 5 years A summary of stock option activity under the Plan for options to employees, officers, directors and consultants, for the year ended December 31, 2017, is presented below: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 2017 566,747 $ 20.46 Granted 120,000 9.00 Exercised (50,800 ) 2.94 Forfeited (516,414 ) 22.16 Outstanding at December 31, 2017 119,533 $ 9.02 9.8 $ 2,316,000 Exercisable at December 31, 2017 119,533 $ 9.02 9.8 $ 2,316,000 The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price on December 31, 2017 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders, had all option holders been able to, and in fact had, exercised their options on December 31, 2017. During the year ended December 31, 2017, 120,000 options were granted under the Plan to directors and officers with a weighted average exercise price at grant date of $9.00 per option. Included in the 120,000 options issued, were 20,000 options at an average exercise price of $4.02 per share which vest monthly over a twenty-four-month period and 100,000 options at an exercise price of $10.00 per share which were vested at grant date. All options were granted under the Company's Plan and expire ten years from the grant date. During the year ended December 31, 2017, 50,800 options outstanding under the Plan were exercised generating $149,136 in cash proceeds. The 50,800 options exercised had a total intrinsic value when exercised of approximately $171,000. During the year ended December 31, 2016, no options were exercised. During the year December 31, 2017, a total of 516,414 options granted under the Plan were forfeited with 515,578 forfeited as part of the equity rights terminations as described in Note 7 and 836 options terminated at the end of their term. Of the total forfeited, 459,414 options were vested, exercisable at an average exercise price of $24.55 and 57,000 were unvested, exercisable at an average exercise price of $2.92. During the year ended December 31, 2016, a total of 25,479 options that were granted under the Plan were forfeited, of which 21,859 were vested and 3,620 were unvested. The vested options were exercisable at an average of $40.49 per share and the unvested options were exercisable at an average of $15.13 per share. The total fair value of stock options granted to employees, directors and consultants that vested and became exercisable during the years ended December 31, 2017 and 2016, was $639,000 and $646,000, respectively. In January 2018, 19,533 vested options granted under the Plan were exercised for cash proceeds of $78,523. A summary of the activity of nonvested options under the Company's Plan to acquire common shares granted to employees, officers, directors and consultants during the year ended December 31, 2017 is presented below: Nonvested Shares Nonvested Shares Underlying Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Nonvested at January 1, 2017 97,738 $ 3.51 $ 2.58 Granted 120,000 9.00 4.25 Vested (160,738 ) 7.82 3.97 Forfeited (57,000 ) 2.92 2.16 Nonvested at December 31, 2017 — $ — $ — At December 31, 2017, based upon employee, officer, director and consultant options granted, there was no unrecognized compensation cost related to stock options to be recorded. Other common stock purchase options and warrants: As of December 31, 2017, in addition to the Plan options discussed above, the Company had outstanding 1,944,895 warrants in connection with offerings that were not issued under the Plan. In March 2017, the Company completed a total of $7.0 million in private placements of securities and in connection with those offerings, granted investors in the offerings, warrants which are classified as equity, exercisable six-months after issuance, to purchase a total of 2,800,000 shares of common stock, with 900,000 warrants at an exercise price of $3.50 per share and 1,900,000 warrants at an exercise price of $3.56 per share, all expiring in March 2020. See Notes 6 and 7. In December 2017, the Company completed a total of $37.0 million in private placements of securities and in connection with those offerings, granted investors in the offerings, warrants which are classified as equity, exercisable six-months after issuance, to purchase a total of 1,646,113 shares of common stock, at an exercise price of $40.00 per share, all expiring in December 2020. See Note 6 and 7. During the year ended December 31, 2016, 95,000 options were granted outside of the Plan and during 2017, these 95,000 options were forfeited. Operating expenses for the years ended December 31, 2017 and 2016, included approximately $88,620 and $56,000, respectively, related to stock-based compensation. Following is a summary of outstanding options and warrants that were issued outside of the Plan for the year ended December 31, 2017: Shares Underlying Options / Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 2017 527,003 $ 13.36 Granted 4,451,113 17.03 Exercised for cash (620,000 ) 3.00 Exercised on a cashless basis (2,244,147 ) - Forfeited (169,074 ) 18.62 Outstanding at December 31, 2017 1,944,895 $ 35.06 2.7 $ 6,135,000 Exercisable at December 31, 2017 298,782 $ 7.87 2.7 $ 6,135,000 The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price on December 31, 2017 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders, had all option holders been able to, and in fact had, exercised their options on December 31, 2017. In connection with a temporary reduction in the exercise price of warrants issued in the March 2017 private offerings to $3.00 per share 620,000 warrants were exercised for cash, resulting in $1,860,000 in proceeds to the Company. (See Note 7) During the year ended December 31, 2017, warrant holders of 2,244,147 common share rights elected to exercise their warrants on a net cashless basis and were issued a net of 1,335,408 shares of common stock in exchange for termination of the warrants. Warrants issued in the May 2013 private offering at an exercise price of $10.88 per common share for 184,147 share rights were surrendered for the issuance of 106,719 common shares. Warrants issued in the March 2017 private offering of common stock at an exercise price of $3.50 per common share for 360,000 share rights were surrendered for the issuance of 214,851 common shares. Warrants issued in the Mach 2017 private offering of convertible notes at an exercise price of $3.56 per common share for 1,700,000 share rights were surrendered for the issuance of 1,013,838 common shares. (See Note 7) During the year ended December 31, 2017, a total of 169,074 options and warrants that were granted outside of the Plan were forfeited. Of the total forfeited, 71,574 warrants expired under their terms and 60,000 options lapsed (15,000 vested and 45,000 unvested) due to the holders' terminations from the Company. The 60,000 options which lapsed were exercisable at an average of $3.78 per share. The remaining 37,500, which were forfeited resulted from negotiated payments made to each holder to waive their rights to the outstanding options. See Note 7. During the year ended December 31, 2016, no warrants were exercised. Subsequent to December 31, 2017, warrants issued in the May 2013 private offering were surrendered for the issuance of 3,215 shares of common stock. Subsequent to December 31, 2017, 100,000 warrants issued in March 2017, were exercised for cash proceeds of $350,000.

Animal Health License Agreement

Animal Health License Agreements	12 Months Ended
	Dec. 31, 2017
Animal Health License Agreements [Abstract]
Animal Health License Agreements	Note 9. Animal Health License Agreements: Effective May 1, 2004 Washington University in St. Louis ("WU") and Riot Blockchain entered into an exclusive license agreement (WU License Agreement) which grants Riot Blockchain exclusive license and right to sublicense WU's technology (as defined under the WU License Agreement) for veterinary products worldwide, except where such products are prohibited under U.S. laws for export. The term of the WU License Agreement continues until the expiration of the last of WU's patents (as defined in the WU License Agreement) expire. Riot Blockchain has agreed to pay minimum annual royalties of $20,000 annually during the term of the WU License Agreement and such amounts are creditable against future royalties. Royalties payable to WU under the WU License Agreement for covered product sales by Riot Blockchain carry a mid-single digit royalty rate and for sublicense fees received by Riot Blockchain carry a low double-digit royalty rate. The WU License Agreement contains customary terms for confidentiality, prosecution and infringement provisions for licensed patents, publication rights, indemnification and insurance coverage. The WU License Agreement is cancelable by Riot Blockchain with ninety days advance notice at any time and by WU with sixty days advance notice if Riot Blockchain materially breaches the WU License Agreement and fails to cure such breach. In July 2012, the Company entered into an exclusive license agreement (the "License Agreement") with Ceva Santé Animale S.A. ("Licensee"), under which the Company granted the Licensee an exclusive royalty-bearing license, until December 31, 2028, to the Company's intellectual property and other assets, including patent rights and know-how, relating to recombinant single chain reproductive hormone technology for use in non-human mammals (the "Company's Animal Health Assets"). The License Agreement is subject to termination by the Licensee (a) for convenience on 180 days prior written notice, (b) in the Licensee's discretion in the event of a sale or other disposal of the Company's animal health assets, (c) in the Licensee's discretion upon a change in control of the Company, (d) for a material breach of the License Agreement by the Company; or (e) in the Licensee's discretion, if the Company becomes insolvent. The License Agreement is also terminable by the Company if there is a material breach of the License Agreement by the Licensee, or if the Licensee challenges the Company's ownership of designated intellectual property. The License Agreement includes a sublicense of the technology licensed to the Company by WU. Under the terms of the WU License Agreement, a portion of license fees and royalties Riot Blockchain receives from sublicensing agreements will be paid to WU. The obligation for such license fees due to WU, totaling $10,000, is included in accrued expenses at December 31, 2017. Under the License Agreement, the Licensee obtained a worldwide exclusive license to develop, seek regulatory approval for and offer to sell, market, distribute, import and export luteinizing hormone ('LH') and/or follicle-stimulating hormone ("FSH") products for bovine (cattle), equine and swine in the field of the assistance and facilitation of reproduction in bovine, equine and swine animals. The Company also granted the Licensee an option and right of first refusal to develop additional animal health products outside of the licensed field of use or any diagnostic pregnancy detection tests for non-human mammals. Under the License Agreement as of December 31, 2017, the following future milestone payments are provided, assuming future milestones are successfully achieved: ● Milestone payments, totaling up to a potential of $1.1 million in the aggregate, based on the satisfactory conclusion of milestones as defined in the License Agreement; ● Potential for milestone payments of up to an additional $2 million for development and receipt of regulatory approval for additional licensed products; and ● Royalties, at low double-digit rates, based on sales of licensed products. Revenue recognition related to the License Agreement and WU License Agreement is based primarily on the Company's consideration of ASC 808-10-45, "Accounting for Collaborative Arrangements". For financial reporting purposes, the license fees and milestone payments received from the License Agreement, net of the amounts due to third parties, including WU, have been recorded as deferred revenue and are amortized over the term of the License Agreement. License fees and milestone revenue totaling a net of approximately $1,556,000 commenced being amortized into income upon the July 2012 date of milestone achievement. As of December 31, 2017, deferred revenue of $96,698 has been classified as a current liability and $968,617 has been classified as a long-term liability. The current liability represents the next twelve months' portion of the amortizable milestone revenue. For each of the years ended December 31, 2017 and 2016, approximately $97,000, was recorded as the amortized license fee revenue. A tabular summary of the revenue categories and cumulative amounts of revenue recognition associated with the License Agreement follows: Category Totals License fees and milestone amounts paid / achieved $ 1,920,000 Third party obligations recorded, including WU (363,700 ) Deferred revenue balance 1,556,300 Revenue amortization to December 31, 2017 ($394,286 to December 31, 2016) (490,985 ) Net deferred revenue balance at December 31, 2017 ($1,162,014 to December 31, 2016) $ 1,065,315 Commencement of license fees revenue recognition Upon signing or receipt Commencement of milestone revenue recognition Upon milestone achievement over the then remaining life Original amortization period 197 months

Acquisition and Discontinued Op

Acquisition and Discontinued Operations	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Acquisition and Discontinued Operations	Note 10. Acquisition and Discontinued Operations: A. BDI 2016 Acquisition: On September 12, 2016, the Company completed the strategic acquisition of BDI, a privately-held entity. Pursuant to a purchase agreement (the "Purchase Agreement"), through a wholly-owned subsidiary ("Venaxis Sub"), the Company acquired all of the outstanding shares of Series 1 Preferred Stock of BDI from the selling shareholders (the "Seller"), representing more than 98% of the outstanding voting stock of BDI, and BDI thereupon become a majority owned subsidiary of the Company. Under the terms of the Purchase Agreement, the consideration consisted of an aggregate of 627,010 shares of the Company's common stock (the "Shares") which Shares were distributed in accordance with the liquidation preferences set forth in BDI's Fifth Amended and Restated Certificate of Incorporation, as amended. The Shares were valued at approximately $2,577,000 (based upon the closing value of our common stock on the acquisition date) and the issuance represented approximately 14% of the Company's then outstanding common stock at the closing. The Purchase Agreement contained customary representations and warranties of the parties, including BDI, and the Sellers have customary indemnification obligations to the Company relating to BDI, which are subject to certain limitations described further in the Purchase Agreement. The issuance of the Shares was completed as a private placement of securities. The Company also entered into a registration rights agreement with the Sellers. The total consideration transferred consisted of the 627,010 shares of the Company's common stock with a value of $2,577,000. Under the acquisition method of accounting, the total estimated purchase consideration was allocated to the acquired tangible and intangible assets and assumed liabilities based on their estimated fair values as of the acquisition date. Following was the allocation of the purchase consideration: Cash and cash equivalents $ 17,000 Accounts receivable 21,000 Inventory 379,000 Prepaid and other assets 51,000 Equipment 1,000 Identifiable intangible assets: Trademarks (5 year estimated useful life) 99,000 Customer base (6 year estimated useful life) 37,000 Developed technology (4 year estimated useful life) 1,864,000 Total identifiable intangible assets 2,000,000 Goodwill 430,000 Accounts payable (118,000 ) Accrued and other liabilities (175,000 ) Non-controlling interest (29,000 ) Purchase price $ 2,577,000 Intangible assets acquired consisted of the following as of December 31, 2016: Trademarks $ 99,000 Customer base 37,000 Developed technology 1,864,000 Total 2,000,000 Less accumulated amortization (148,264 ) Balance at December 31, 2016 $ 1,851,736 As of November 30, 2016, the Company paid approximately $29,000 to acquire the non-controlling interest in BDI, which was accounted for as an equity transaction. The unaudited supplemental pro forma information for the nine months ended September 30, 2016, as if the BDI acquisition had occurred as of January 1, 2016, would have reflected total revenue of $174,000, net loss of $2,102,000 and loss per share of $0.47. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments to reflect the pro forma results of operations as if the acquisition had occurred as of the beginning of the periods presented, such as increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities. As of December 31, 2016, inventories, included with current assets of discontinued operations, totaled approximately $416,000, consisting of $188,000 in raw materials and $228,000 in finished goods, all associated with the BDI operations. As of December 31, 2017, no inventories were on hand. B. Discontinued operations: During the quarter ended March 31, 2017, the Company made the decision to discontinue the operations of its wholly-owned subsidiary BDI. BDI had developed a proprietary Enhanced Surface Plasmon Resonance technology platform for the detection of molecular interactions. The decision to adopt this plan was made following an evaluation by the Company's Board of Directors in January 2017 of the estimated results of operations projected during the near to mid-term period for BDI, including consideration of product development required and updated sales forecasts, and estimated additional cash resources required. The Company expects to dispose of the assets and operations during 2017 by selling the assets and licensing the intellectual property rights. The Company has recognized the exit of BDI in accordance with Accounting Standards Codification (ASC) 205-20, Discontinued Operations The Company's historical financial statements have been revised to present the operating results of the BDI business as a discontinued operation. Assets and liabilities related to the discontinued operations of BDI are approximately as follows as of December 31, 2017 and 2016: 2017 2016 Current assets: Accounts receivable $ - $ 5,000 Inventories - 416,000 Prepaid expenses - 66,000 Total current assets $ $ 487,000 Equipment and furnishings, net $ - $ 36,000 Intangible assets, net - 2,281,000 Deposit - 37,000 Total noncurrent assets $ - $ 2,354,000 Current liabilities: Accounts payable $ 16,000 $ 174,000 Accrued expenses 28,000 85,000 Deferred revenue 137,000 - Total current liabilities $ 181,000 $ 259,000 Summarized results of the discontinued operation are as follows for the years ended December 31, 2017 and 2016: 2017 2016 Sales $ 37,000 $ 9,000 Cost of sales 6,000 3,000 Gross margin 31,000 6,000 Operating expenses 955,000 1,121,000 Operating (loss) (924,000 ) (1,115,000 ) Escrow forfeiture gain 135,000 - Impairment (loss) (2,754,000 ) - (Loss) from discontinued operations $ (3,543,000 ) $ (1,115,000 ) Included in the impairment loss recognized for the year ended December 31, 2017 on the discontinuance of BDI are impairment losses recognized on inventories of $453,000, equipment and furnishings of $29,000, identifiable intangible assets of $1,833,000, goodwill of $430,000, and a $9,000, net expense from all other items, all associated with the assets and operations of BDI. For the year. Additional costs associated with the exit of operations of the Company's subsidiary BDI may be incurred as final wrap-up of BDI's operations are completed. In December 2017, BDI entered an asset purchase agreement with a privately held third party (the "Buyer"), pursuant to which BDI sold its intellectual property, technology rights and know-how associated with the business to the Buyer. Should the Buyer decide to pursue development of the acquired rights and if they successfully commercialize a product using the acquired rights, BDI would be entitled to receive future earn-out payments based upon a low single digit percentage of such defined sales. Such earn-out payments are subject to certain per product sale limitations and a cumulative payment ceiling (not to exceed total payments of low single-digit millions of dollars). Based upon the Company's assessment of the current low likelihood receiving future payments under this agreement, no revenue has been recognized.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income taxes	Note 11. Income taxes: The Company's income tax benefit for the year ended December 31, 2017 totaled $1,609,000 and resulted from the difference in book and tax basis of the Kairos mining equipment and its deprecation and impairment expense for the year ended December 31, 2017. There was no income tax expense due to operating loss incurred for the year ended December 31, 2016. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"), which makes broad and complex changes to the U.S. tax code. Certain of these changes may be applicable to the Company, including but not limited to, reducing the U.S. federal corporate tax rate from 34 percent to 21 percent, creating a new limitation on deductible interest expense, eliminating the corporate alternative minimum tax ("AMT"), modifying the rules related to uses and limitations of net operating loss carryforwards generated in tax years ending after December 31, 2017, and changing the rules pertaining to the taxation of profits earned abroad. Changes in tax rates and tax laws are accounted for in the period of enactment. The Tax Act reduces the corporate tax rate to 21 percent, effective January 1, 2018. Consequently, we have recorded a decrease related to deferred tax assets of approximately $14.0 million dollars exclusive of the corresponding change in the valuation allowance, for the year ended December 31, 2017. Due to the full valuation allowance on the deferred tax assets, there is no net adjustment to deferred tax expense or benefit due to the reduction of the corporate tax rate. The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2017 and 2016 are comprised of the following: As of December 31, 2017 2016 Deferred tax assets/(liabilities): Net operating loss carryforwards $ 25,837,000 $ 36,817,000 Research and development credit carryforwards 989,000 1,103,000 Stock option expense 252,000 - Property and equipment - 50,000 Capital loss carryforward - 444,000 Other 14,000 (22,000 ) Deferred tax asset 27,092,000 38,392,000 Valuation allowance (26,393,000 ) (38,392,000 ) Deferred income tax liability $ 699,000 $ - The deferred tax asset as of December 31, 2017 includes approximately $0.9 million related to discontinued operations. The Company recognized a $2,308,000 deferred tax liability in 2017 as a result of the acquisitions of Tess and Kairos in November 2017. Due to the acquisition, a temporary difference between the book fair value and the tax basis of the property and equipment acquired created an approximately $2,308,000 deferred tax liability and additional asset values were recorded. At December 31, 2017, the Company had net operating loss carry forwards for federal and state tax purposes of approximately $105 million which expires in 2037. The Company has not performed a detailed analysis to determine whether an ownership change under Section 382 of the IRC has occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of net operating loss carryforwards attributable to periods before the change. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. In case the deferred tax assets will not be realized in future periods, the Company has provided a valuation allowance for the full amount of the deferred tax assets at December 31, 2017. The valuation allowance decreased by approximately $9.4 million as of December 31, 2017. The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows: For the years ended December 31, 2017 2016 Statutory federal income tax benefit (7,307,000 ) $ (1,453,000 ) State taxes, net of federal tax benefit (647,000 ) (128,000 ) Federal tax rate change and other adjustments 13,617,000 239,000 Stock compensation and other non-deductible expenses 3,118,000 - Change in valuation allowance (10,390,000 ) 1,342,000 Income taxes provision (benefit) $ (1,609,000 ) $ - The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2017.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Note 12. Commitments and contingencies: Commitments: The Company's subsidiary, BDI, had a lease commitment on its office and laboratory space that was scheduled to expire March 31, 2018, requiring future non-cancellable lease payments as of May 2017 of approximately $294,000 for the remainder of its original term. During May 2017, an agreement with the subsidiary's landlord was reached to terminate the lease by surrendering the facility in May 2017, making a $80,419 prepayment of rent through July 31, 2017 and surrendering the $37,000 lease deposit. Rent expense for the year ended December 31, 2017 totaled approximately $239,000, including $216,000 in rent expense for BDI, inclusive of the payment of the early termination fee and the surrender of the $37,000 lease deposit and $23,000 in rent expense incurred by the Company under short-term rent agreements. The Company's rent expense for the year ended December 31, 2016 totaled approximately $120,000 which included $92,000 in rent expense related to BDI's facility expense for the period from acquisition to December 31, 2016. See Note 14 for new lease agreement commitment subsequent to December 31, 2017. On February 25, 2016, the Company completed the sale of its corporate headquarters, land, building and certain fixtures and equipment to a third party at a purchase price of $4,053,000. The sale resulted in a gain of approximately $1,933,000 and generated approximately $1,799,000 in net cash after expenses and mortgage payoffs. During a portion of 2017 the Company rented space in the building under short-term lease agreement that provided certain storage space. As of December 31, 2017, the Company has employment agreements with two officers providing aggregate annual minimum commitments totaling approximately $572,000. The agreements contain customary confidentiality and benefit provisions. Contingencies: On February 17, 2018, Creighton Takata filed an action asserting putative class action claims on behalf of the Riot Blockchain, Inc.'s shareholders in the United District Court for the District of New Jersey, Takata v. Riot Blockchain Inc., et al., Case No. 3:18-cv-02293. The complaint asserts violations of federal securities laws under Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 on behalf of a putative class of shareholders that purchased Riot Blockchain, Inc. stock from November 13, 2017 through February 15, 2018. The complaint alleges that Riot Blockchain, Inc. and certain of its officers and directors (John O'Rourke and Jeffrey G. McGonegal) made, caused to be made, or failed to correct false and/or misleading statements in press releases and public filings regarding Riot Blockchain, Inc.'s business plan in connection with its cryptocurrency business. The complaint requests damages in unspecified amounts, costs and fees of bringing the action, and other unspecified relief. The company and the individual defendants deny any allegations of wrongdoing and intend to vigorously defend against this lawsuit. Two additional, nearly identical complaints were subsequently filed by Richard Roys and Bruce Greenawalt in the United District States Court for the Southern District of Florida (Roys v. Riot Blockchain Inc., et al., Case No. 9:18-cv-80225) and the United States District Court for the District of Colorado (Greenawalt v. Riot Blockchain Inc., et al., Case No. 1:18-cv-00440), respectively. Mr. Roy's complaint also names Barry Honig, an investor in Riot Blockchain, Inc., as a defendant. On March 27, 2018, the court closed the Roys case for administrative purposes. On April 2, 2018, Mr. Greenawalt filed a notice of voluntary dismissal of his action, which the court entered on the same date. On April 5, 2018, Michael Jackson filed a shareholder derivative complaint on behalf of the Company in the Supreme Court of the State of New York, County of Nassau, against certain of the Company's officers and directors (John O'Rourke, Jeffrey G. McGonegal, Andrew J. Kaplan, Jason Les and Eric So), as well as against Mr. Honig. The complaint contains similar allegations to those contained in the shareholder class action complaints and seeks recovery for alleged breaches of fiduciary duty, unjust enrichment, waste of corporate assets, abuse of control and gross mismanagement. The complaint seeks unspecific monetary damages and corporate governance changes. The company and the individual defendants deny any allegations of wrongdoing and intend to vigorously defend against this lawsuit. The Company is currently not a party to any other legal proceedings, the adverse outcome of which would, in the Company's opinion, have a material adverse effect on our business, financial condition and results of operations. On April 9, 2018, the Company received a subpoena requesting document from the U.S. Securities and Exchange Commission. We intend to fully cooperate with the SEC inquiry. As part of its review of the Company's public filings, the Securities and Exchange Commission ("SEC") has inquired about certain of the Company's assets' classification as, and amount of, possible Investment Company assets. The Company is responding to the SEC's inquiries. Should an ultimate determination be made that the Company was or is an inadvertent Investment Company, it could have an impact on the Company's decision to hold certain assets and / or the Company's financial reporting. The Company's position is that it was or is not subject to the Investment Company regulations.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 13. Related Party Transactions Per Schedules 13D filed with the Securities and Exchange Commission, each of Barry Honig (together with other group members) and Catherine Johanna DeFrancesco beneficially owned greater than 10% of the dispositive and voting power of the Company's common stock. Mr. Honig reported beneficial ownership of approximately 11.2% of the Company's common stock as of January 5, 2017 and Ms. DeFrancesco reported beneficial ownership of approximately 11.45% of the Company's common stock as of January 10, 2017. Mr. Honig invested $1,750,000 in the March 2017 Convertible Note Private Placement (see Note 7). GRQ Consultants, Inc., a related party of Mr. Honig, received a cash payment of $50,000 for diligence services in connection with the Company's investment in Coinsquare (see Note 4). Each of Mr. Honig and Ms. DeFrancesco was a shareholder of Kairos at the time of its acquisition by the Company (see Note 2), with Mr. Honig having owned approximately 8.6% of Kairos and Ms. DeFrancesco having owned approximately 6.3% of Kairos. Each of Mr. Honig and Ms. DeFrancesco invested in the December 2017 Common Share Private Placement, with Mr. Honig investing $500,000 and Ms. DeFrancesco investing $360,000 (see Note 7).

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events Bitcoin Auction In January 2018, through a sealed bid auction conducted by the U.S. Marshals Service, the Company acquired 500 bitcoins for approximately $5,625,000. Asset Purchase Agreement with Prive Technologies LLC On February 21, 2018, the Company and Kairos Global Technology Inc., a wholly-owned subsidiary of the Company ("Kairos"), completed an asset purchase under an agreement (the "Prive Purchase Agreement") with Prive Technologies LLC ("Prive"), on behalf of certain persons and entities who owned certain bitcoin mining machines and related equipment (the "Prive Equipment"). Pursuant to the Purchase Agreement, the aggregate consideration for the Prive Equipment consisted of (i) Eleven Million Dollars ($11,000,000) and (ii) One Million (1,000,000) shares of the Company's common stock, no par value per share (the " Prive Shares"). Upon closing of the transaction, and pursuant to the terms of the Purchase Agreement, Kairos became the owner of the Prive Equipment and other assets used for the mining of cryptocurrency, including, but not limited to, 3,800 Bitmain AntMiner S9s. Mr. Michael Ho and Mr. Bryan Pascal were selling shareholders of Prive, with Mr. Ho owning approximately 24.8% of Prive and Mr. Pascal owning approximately 18.4% of Prive, at the time of its acquisition by the Company. In November 2017, at the time of the Kairos acquisition, (see Note 2), Mr. Ho and Mr. Pascal became Series B Preferred Shareholders of the Company having owned approximately 10.7% and 5.7%, respectively of Kairos at the time of its acquisition by the Company. Prive Shares were deposited into an escrow account with an escrow agent to be held in escrow as provided in an escrow agreement. Under this escrow agreement, the escrowed Prive Shares will be released to the Sellers upon the later of August 21, 2018 and the date on which the Company and Kairos have generated Net Cash Flow (as defined in the Prive Purchase Agreement) of at least Ten Million Dollars ($10,000,000) from the Prive Equipment. If the Escrow Shares have not been released to the Sellers on or before February 21, 2020, then these escrowed Prive Shares shall be returned to the Company for cancellation. The Company has commenced an evaluation of the financial reporting for this transaction considering the provisions of FASB ASU 2017-01, Business Combinations (Topic 805). The assessment is preliminary and subject to additional evaluation, with the transaction expected to be accounted for as an acquisition of assets based on the estimated fair value as of the acquisition date. Asset Purchase Agreement with Blockchain Mining Supply & Services Ltd. On February 21, 2018, the Company completed an asset purchase under an agreement (the "BMSS Purchase Agreement") with Blockchain Mining Supply & Services Ltd. ("BMSS"), which owned 3,000 AntMiner S9 bitcoin mining machines (the "BMSS Equipment"). Pursuant to the BMSS Purchase Agreement, the Company purchased the BMSS Equipment for aggregate consideration of Eight Million Five Hundred Thousand Dollars ($8,500,000). Seven Million Dollars ($7,000,000) of the purchase price was paid at closing. The remaining One Million Five Hundred Thousand Dollars ($1,500,000) of the purchase price shall be payable on the earlier of August 20, 2018 and such time when the BMSS Equipment becomes operational. Ingenium International LLC Consulting Agreement. On February 21, 2018, the Company entered into a Consulting Agreement with Ingenium International LLC (the "Consultant") to provide consulting services related to the Company's business for a 12-month period. Certain members of the Consultant were also affiliated with Prive. Pursuant to the Consulting Agreement Consultant's services are defined as follows: complete the installation and deployment of 8,000+ ASIC cryptocurrency miners, which included the Prive Equipment and the BMSS Equipment; assist in managing and monitoring the operation of the 8,000+ cryptocurrency miners on an ongoing basis; promptly responding to and troubleshooting any issues as they arise in the management and monitoring of the operations; continuing the buildout of up to 40 Megawatts of energy capacity, with the ultimate goal to secure the power and build the location for up to 80 Megawatts of energy capacity; and to make strategic introductions to other cryptocurrency business opportunities and contacts in the sector. In connection with the Consulting Agreement the Company made a lump sum payment of $4,000,000 to the Consultant. Mr. Michael Ho and Mr. Bryan Pascal are controlling principals of Ingenium International LLC. As disclosed in this Note 14 above and Note 2, Mr. Ho and Mr. Pascal are shareholders in the Company by virtue of the previous Kairos and Prive transactions. Oklahoma Lease Agreement. On February 27, 2018, Kairos ("Tenant") entered into a lease agreement (the "Lease") with 7725 Reno #1, LLC (the "Landlord"), pursuant to which the Tenant leases an approximately 107,600 square foot warehouse located in Oklahoma City, Oklahoma, including improvements thereon. Pursuant to the terms of the Lease, the initial term of one year terminates on February 15, 2019, unless terminated earlier pursuant to the terms of the Lease, subject to the Tenant's options to renew the Lease. Tenant has four one-year renewal options that may be exercised so long as Tenant is not in default, subject to increases in base rent. Tenant has the right to operate from the premises on a 24 hour/seven day a week basis. At least three months, but no more than six months, prior to the expiration of the initial Lease term or renewal term, as applicable, Tenant shall give Landlord written notice of its intent to exercise the applicable renewal option, which also includes incremental payment for additional electric capacity delivery. If Tenant does not elect to exercise a renewal option, all remaining renewal options, if any, shall terminate. Base rent for the premises during the first 12 months is equal to $55.95/kW per month for a total of 4 Megawatts (MW) of available electrical power, or $223,800 per month. Base rent is calculated based upon the monthly electrical power made available to Tenant within the premises, and not based on Tenant's actual usage. In connection with the Lease, Parent has provided a limited guarantee of Tenant's failure to make payment of base rent or additional rent pursuant to the Lease. As soon as practicable after the effective date of the Lease, Landlord, at Landlord's expense, agreed to provide additional 12.5 kV transformer equipment to increase the electrical power available for Tenant's use by an additional 2MW, which will result in additional rent of $55.12/kW for the additional 2MW of power when it is made available. Provided that Tenant is not in default under the Lease beyond any applicable notice and cure periods, Tenant may request Landlord to further increase the electrical power available, in increments from 6.01 MW up to 12.0 MW, by giving written notice to Landlord of the requested increase. Landlord, at Landlord's expense, would then provide an additional 12.5kV of electrical transforming equipment to increase the electrical power available for Tenant's use by the additional MW requested by Tenant. Effective as of the date the additional power is made available to Tenant, base rent will increase by an amount equivalent to the additional MW requested by Tenant multiplied by $55.12 per kW. If Tenant exercises all of its renewal options, then the base rent for the first 4MW of available power would increase to $57.63 per kW in year two, $59.36 per kW in year three, $61.14 per kW in year four and $62.97 per kW in year five. In each case, available power of greater than 4MW and up to 12MW would result in base rent of $55.12 per kW. On March 26, 2018, Kairos entered into a first amendment to the above lease (the "Lease Amendment"), whereby 7725 Reno agreed to increase the electrical power available for Kairos's use from 6MW to 12MW, and the base rent under the lease was increased to approximately $665,760 per month, effective as of the date when such additional power is available. Kairos Operations and Equipment Status. During January 2018 certain infrastructure deficiencies in the Kairos short-term rented facility in Quebec, Canada became more problematic. Kairos noted that due to storm water leakage into the facility, servers consisting of 90 AntMiner S9s and 29 AntMiner L3s had visible evidence of exposure to water. These servers were taken off line and Kairos is currently investigating the extent of possible damage and functionality of the 119 servers. Kairos has notified the landlord regarding a possible claim for damage and loss. While the extent of the damage, if in fact the units are damaged, has not been determined or quantified, the total fair value cost of the servers was approximately $426,000. Kairos' ability to recover all or any portion of the damage and loss, should the servers in fact be damaged or unusable, has not been determined. As a result of the issues with the Kairos original rented facility and the subsequent execution of the lease of the approximate 107,600 square foot warehouse located in Oklahoma City, Oklahoma Lease with 7725 Reno #1, LLC, as discussed above, Kairos determined to take all 1,200 of the servers acquired in the Kairos November 3, 2017, acquisition off-line in Canada and relocate them to the new facility. This was completed in March 2018 for all of the servers except the 119 servers that showed visible signs of damage, which are still being evaluated at the facility in Quebec, Canada Acquisition of Logical Brokerage Corp. On March 26, 2018, the Company entered into and closed a stock purchase agreement (the "Logical Brokerage Purchase Agreement") between the Company and Mark Bradley Fisher (the "Logical Brokerage Seller"). Pursuant to the Logical Brokerage Purchase Agreement, the Company purchased from the Logical Brokerage Seller 9.25 shares of Logical Brokerage Corp. ("Logical Brokerage"), representing 92.5% of the outstanding capital stock of Logical Brokerage, for a cash purchase price of $600,000. Logical Brokerage, a futures introducing broker headquartered in Miami, FL is registered with the Commodity Futures Trading Commission, or CFTC, and a member of the National Futures Association, or NFA. As of the date of these financial statements the initial accounting for the business combination with Logical Brokerage is incomplete and the Company is currently not able to provide additional financial disclosures, including pro forma information, that might be required. In connection with the closing of the Logical Brokerage Purchase Agreement, on March 26, 2018, the Company entered into a stockholders' agreement (the "Stockholders Agreement") with Logical Brokerage and Mark Bradley Fisher. The Stockholders Agreement provides, among other things, that, subject to certain exceptions, the Logical Brokerage Seller may not transfer any of his remaining shares of Logical Brokerage without the written consent of the Company. The Stockholders Agreement also provides that, subject to certain exceptions, in the event the Company proposes to transfer 35% or more of Logical Brokerage's total issued and outstanding capital stock, the Logical Brokerage Seller will be entitled to certain "tag-along" rights. Corporate Lease Agreement. On April 9, 2018 the Company entered into a commercial lease covering 1,694 rentable square feet of office space in Fort Lauderdale, FL, with a third-party. The lease is for an initial term of thirty-nine months, with one five-year option to renew. The lease requires initial monthly rent of approximately $7,000, including base rent and associated operating expenses.

Organization and summary of s21

Organization and summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of operations	Nature of operations: Riot Blockchain, Inc. (the "Company" or "Riot Blockchain") was organized on July 24, 2000, as a Colorado corporation. Effective October 19, 2017, the Company's name was changed to Riot Blockchain, Inc., from Bioptix, Inc., and as of November 30, 2016, the Company's name was changed to Bioptix, Inc., from Venaxis, Inc. Effective October 19, 2017, the Company was re-incorporated to Nevada from Colorado. On October 2, 2017 the Board of Directors of the Company approved a merger (the "Merger") of the Company with its wholly-owned subsidiary, Riot Blockchain, Inc., a Nevada corporation (the "Merger Sub"), solely for the purpose of changing the name of the Company. Upon consummation of the Merger, the separate existence of Merger Sub ceased. As permitted by Chapter 92A.180 of Nevada Revised Statutes, the purpose of the Merger was to effect a change of the Company's name to Riot Blockchain, Inc. from Bioptix, Inc. Upon approval by NASDAQ, on October 19, 2017, the Company's name was thereupon changed. The Company is building a cryptocurrency mining operation, operating specialized computers (also known as "miners") that generate cryptocurrency (primarily Bitcoin). As of December 31, 2017, the Company owned 1,200 miners acquired with the Kairos Global Technology, Inc., ("Kairos") acquisition in November 2017. During February 2018 in two separate transactions the Company acquired an additional 6,800 miners bringing the total miners owned to 8,000. During February 2018, Kairos entered into a lease agreement for approximately a 107,000-square foot facility in Oklahoma City, Oklahoma, which included data center improvements. Upon the execution of the facility lease the Company began consolidating all of its miners at the data center facility. As of March 31, 2018, 3,500 of the miners were installed and operating. Legacy Operations – Historically, the company has been an in vitro diagnostic company. The Company's business had been in the development and commercialization of innovative products that address unmet diagnostic and therapeutic needs. Until 2016, when determined that it was not prudent to use the Company's financial resources to continue to advance development of the APPY APPY APPY The Company holds an exclusive license agreement with Washington University ("WU") in St. Louis which granted the Company an exclusive license and right to sublicense its technology for veterinary products worldwide, subject to certain exceptions. In July 2012, the Company granted Ceva Sante Animale S.A. ("Ceva") an exclusive royalty-bearing license to the Company's intellectual property and other assets, relating to recombinant single chain reproductive hormone technology for use in non-human mammals. This license includes a sublicense of the technology licensed to the Company by WU. Ceva continues to advance development of the bovine rFSH product and cumulative cash payments received to date by the Company from Ceva are approximately $2 million. Through BiOptix Diagnostics, Inc., ("BDI") the Company's wholly owned subsidiary which was acquired in September 2016, the Company developed a proprietary Enhanced Surface Plasmon Resonance technology platform for the detection of molecular interactions. The Company acquired a Surface Plasma Resonance ("SPR") platform which seeks to combine high sensitivity with microarray detection capability to allow researchers to understand whether their target molecules have functionality against the disease targeted. SPR is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. Effective January 14, 2017, a plan was adopted to exit this acquired business and commenced a significant reduction in the workforce. The decision to adopt this plan was made following an evaluation by the Company's Board of Directors in January 2017, of the estimated results of operations projected during the near to mid-term period for BDI, including consideration of product development required and updated sales forecasts, and estimated additional cash resources required. See Note 10.
Management's plans and basis of presentation	Management's plans and basis of presentation: The Company has experienced recurring losses and negative cash flows from operations. At December 31, 2017, the Company had approximate balances of cash and cash equivalents of $41,652,000, working capital of $41,350,000, total stockholders' equity of $48,869,000 and an accumulated deficit of $139,263,000. To date, the Company has in large part relied on equity financing to fund its operations. The recently completed Kairos Global Technology, Inc. ("Kairos") and Tess, Inc., ("Tess") acquisitions and the goNumerical, Ltd. (d/b/a "Coinsquare") investment, as well as a new name, reflect a new focus (in addition to veterinary and life science oriented businesses of the Company) being pursued by the Company. The decision to invest in companies exposed to blockchain and digital currency related risks is a strategic decision by the Company. The Company's strategy will be to continue to pursue opportunistic investments and controlling positions in these new and emerging technologies which will continue to expose the Company to the numerous risks and volatility associated with this sector. Effective January 14, 2017, the Company adopted a plan to exit the business of BDI and commenced a significant reduction in the workforce. The decision to adopt this plan was made following an evaluation by the Company's Board of Directors in January 2017, of the estimated results of operations projected during the near to mid-term period for BDI, including consideration of product development required and updated sales forecasts, and estimated additional cash resources required. Accordingly, the historical results of BDI have been classified as discontinued operations for all periods presented. The Company expects to continue to incur losses from operations for the near-term and these losses could be significant as the Company incurs costs and expenses associated with the recent and potential future acquisitions and investments, as well as public company and administrative related expenses are incurred and winding-down BDI's operations. The Company believes its upcoming near-term cash needs relative to the recent acquisitions will be covered by cash acquired in the acquisitions combined with the Company's available cash. The Company believes that its current working capital position will be sufficient to meet its estimated cash needs for at least a year and a day from this filing. The Company is closely monitoring its cash balances, cash needs and expense levels. Management's strategic plans include the following: • continuing to evaluate opportunities for investments in the blockchain and digital currency sector; • exploring other possible strategic options and financing opportunities available to the Company; • evaluating options to monetize, partner or license the Company's assets, including the appendicitis product portfolio; and • continuing to implement cost control initiatives to conserve cash.
Principles of consolidation	Principles of consolidation The accompanying consolidated financial statements of the Company include the accounts of the Company and its wholly or majority owned and controlled subsidiaries. Consolidated subsidiaries results are included from the date the subsidiary was acquired. Intercompany investments, accounts and transactions have been eliminated in consolidation. Non–controlling interests represents the minority equity investment in the Company's subsidiaries, plus the minority investors' share of the net operating results and other components of equity relating to the non–controlling interest. The Company's consolidated subsidiaries and (percentage owned at December 31, 2017) consisted of; Kairos Global Technology, Inc., (100%) Tess, Inc., (52%) BiOptix Diagnostics, Inc., (100%).
Investment in affiliate	Investment in affiliate The Company's investment in Coinsquare is accounted for using the cost method. In assessing its accounting method, the Company considered guidance under ASC 323-10 and SEC Rule 3.09 relating to the percentage of ownership and the lack of factors indicating significant influence.
Cash, cash equivalents and short-term investments	Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company's cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. The Company invests excess cash from time to time in highly-liquid debt and equity investments of highly-rated entities, which are classified as trading securities. Such amounts are recorded at market values using Level 1 inputs in determining fair value and are generally classified as current, as the Company does not intend to hold the investments beyond twelve months. Investment securities classified as trading are those securities that are bought and held principally for the purpose of selling them in the near term, with the objective of preserving principal and generating profits. These securities are reported at fair value with unrealized gains and losses reported as an element of other (expense) income in current period earnings. As of December 31, 2017, and 2016, approximately 100% and 41%, respectively, of the investment portfolio was in cash and cash equivalents, which is presented as such on the accompanying balance sheet. For the years ended December 31, 2017 and 2016, there were approximately $16,000 and $22,000, respectively, in management fee expenses. The Company's short-term investments comprise certificates of deposit, commercial paper and corporate bonds, all of which are classified as trading securities and carried at their fair value based upon quoted market prices of the securities. Net realized and unrealized gains and losses on trading securities are included in net loss. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification. The composition of trading securities is as follows at December 31, 2017 and 2016: 2017 2016 Cost Fair Value Cost Fair Value Certificates of deposit / commercial paper $ — $ — $ 2,378,222 $ 2,373,891 Corporate bonds — — 5,138,182 5,132,870 Total trading securities $ — $ — $ 7,516,404 $ 7,506,761 Investment income for the years ended December 31, 2017 and 2016 consists of the following: 2017 2016 Interest income $ 104,886 $ 126,296 Realized gains (losses) (21 ) (3,316 ) Unrealized gains (losses) 9,893 20,641 Management fee expenses (15,503 ) (21,897 ) Net investment income $ 99,255 $ 121,724
Fair value of financial instruments	Fair value of financial instruments: The Company accounts for financial instruments under Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic (ASC) 820, Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company's market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. There were no financial assets or liabilities measured at fair value, with the exception of cash, cash equivalents (level 1), short-term investments (level 1) digital currencies (level 1), and convertible note receivable (level 3) as of December 31, 2017 and 2016. The carrying amounts of the Company's financial instruments (other than cash, cash equivalents, short-term investments and digital currencies, as discussed above) approximate fair value because of their variable interest rates and / or short maturities combined with the recent historical interest rate levels. The Company uses Level 1 of the fair value hierarchy to measure the fair value of digital currencies and revalues its digital currencies at every reporting period and recognizes gains or losses in the consolidated statements of operations that are attributable to the change in the fair value of the digital currency. Digital currencies financial assets measured at fair value on a recurring basis are summarized below and disclosed on the December 31, 2017, balance sheets as follows: Fair value measurement using Carrying value Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 41,651,965 $ 41,651,965 $ – $ – $ 41,651,965 Digital currencies $ 200,164 $ 200,164 $ – $ – $ 200,164 Convertible note receivable $ 200,000 $ – $ – $ 200,000 $ 200,000
Segment Reporting	Segment Reporting: Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision–making group in deciding how to allocate resources and in assessing performance. Our chief operating decision–making group is composed of the chief executive officer. We currently operate in the Digital Currency Blockchain segment. Certain corporate expenses are not allocated to segment.
Revenue Recognition	Revenue Recognition: In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" (ASU 2014-09) as modified by ASU No. 2015-14, "Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date," ASU 2016-08, "Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing," and ASU No. 2016-12, "Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients." The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company adopted the new standard on January 1, 2018, using the modified retrospective approach. The adoption of ASU 2014-09 did not have a material impact on the Company's consolidated financial statements and related disclosures. The Company recognizes revenue when it is realized or realizable and earned. We consider revenue realized or realizable and earned when there is persuasive evidence of an arrangement and that the product has been shipped or the services have been provided to the customer, the sales price is fixed or determinable and collectability is probable. Our material revenue stream is related to the mining of digital currencies. The Company derives its revenue by providing transaction verification services within the digital currency networks of crypto-currencies, such as Bitcoin, Bitcoin Cash and Litecoin, commonly termed "crypto- currency mining." In consideration for these services, the Company receives digital currencies which are recorded as revenue, using the average U. S. dollar spot price of the related crypto-currency on the date of receipt. The coins are recorded on the balance sheet at their fair value and re–measured at each reporting date. Revaluation gains or losses, as well as gains or losses on sale of digital currencies are recorded as a component of cost of revenues in the statement of operations. Expenses associated with running the crypto-currency mining business, such as equipment deprecation, rent and electricity cost are also recorded as cost of revenues. There is currently no specific definitive guidance in U.S. GAAP or alternative accounting frameworks for the accounting for the production and mining of digital currencies and management has exercised significant judgement in determining appropriate accounting treatment for the recognition of revenue for mining of digital currencies. Management has examined various factors surrounding the substance of the Company's operations and the guidance in ASC 605, Revenue Recognition Revenue recognition related to the license agreement is based upon the licensee's right to use the technology and the Company's ongoing obligations to maintain and defend the patented rights and comply with the terms of the sub-license agreement whereby the license fees and milestone payments received from the agreement, net of the amounts due to third parties, have been recorded as deferred revenue and are amortized over the term of the license agreement.
Property and equipment	Property and equipment: Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, generally two years for crypto-currency machines and three years for computer related assets. See Note 3 for the 2016 sale of the Company's prior land and building.
Patents and other intangible assets	Patents and other intangible assets The Company accounts for intangible assets under ASC 350-30. Patents consisting of legal fees incurred are initially recorded at cost. Patents are amortized over the useful lives of the assets, using the straight-line method. Certain patents are in the legal application process and therefore are not currently being amortized. We review the carrying value of patents at the end of each reporting period.
Goodwill	Goodwill: The Company performs a goodwill impairment analysis in the fourth quarter of each year, or whenever there is an indication of impairment. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation to determine if it is more likely than not that the fair value of its reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a two-step goodwill impairment test. The Company has determined, based on its evaluation, that the goodwill associated with the BDI acquisition was impaired and was written off during the year ended December 31, 2017, included as part of the discontinued operations impairment loss. (See Notes 2 and 10 for goodwill information).
Impairment of long-lived assets	Impairment of long-lived assets: Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Based on its reviews, management determined that its crypto-currency machines where impaired by a total of $5,218,000 based upon an assessment as of December 31, 2017, including consideration of the decline in bitcoin values which occurred commencing in late December 2017 and into 2018. Certain costs previously incurred for patents were determined impaired during the year ended December 31, 2016 comprising approximately $535,000 of net patent costs, resulting from management's decisions not to pursue patents based upon a cost benefit analysis of patent expenses and coverage protection in several smaller world markets that were determined to not have the economic or fiscal potential to make the patent pursuit viable. Impairment charges are included in research and development expenses in the accompanying statements of operations. Intangible assets acquired in the Tess business combination consist primarily of in-process research and development ("IPR&D") assets. The value attributable to IPR&D projects at the time of acquisition is capitalized as an indefinite-lived intangible asset and tested for impairment until the project is completed or abandoned. Upon completion of the project, the indefinite-lived intangible asset will be accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the project is abandoned, the indefinite-lived intangible asset will be charged to expense.
Research and development	Research and development: Research and development costs are charged to expense as incurred.
Use of estimates	Use of estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company's financial statements include estimates associated with revenue recognition, asset valuations and useful lives in business combinations, impairment analysis of intangibles and stock-based compensation.
Business Combinations	Business Combinations: The Company accounts for acquisitions under ASC Topic 805, Business Combinations and Reorganizations When acquiring a business, the Company allocates the purchase price to the assets acquired and liabilities assumed in the transaction at their respective estimated fair values transaction costs are expensed. Any premium over the fair value of net assets acquired are recorded as goodwill. The allocation of the purchase price involves judgments and estimates both in characterizing the assets and in determining their fair value. The way the Company characterizes the assets has important implications, as long-lived assets with definitive lives, for example, are depreciated or amortized, whereas goodwill is tested annually for impairment. With respect to determining the fair value of assets, the most subjective estimates involve valuations of long-lived assets, such as property, plant, and equipment as well as identified intangible assets. The Company uses all available information to make these fair value determinations and may engage independent valuation specialists to assist in the fair value determination of the acquired long-lived assets. The fair values of long-lived assets are determined using valuation techniques that use discounted cash flow methods, independent market appraisals and other acceptable valuation techniques.
Income taxes	Income taxes: The Company accounts for income taxes under the asset and liability method, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is required to the extent any deferred tax assets may not be realizable. ASC Topic 740, Income Taxes, ("ASC 740"), also clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company's evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company's consolidated financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position.
Stock-based compensation	Stock-based compensation: The Company recognizes the cost of employee services received in exchange for an award of equity instruments in the financial statements which is measured based on the grant date fair value of the award. Stock-based compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (generally the vesting period). The value of restricted stock grants are measured based on their fair market value on the date of grant and amortized over their respective vesting periods, generally twenty-four months. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model.
Income (loss) per share	Income (loss) per share ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share ("EPS") with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Basic net income (loss) per share includes no dilution and is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding for the period, including any vested but unissued restricted common shares and excluding any nonvested restricted common shares. Diluted net income (loss) per share reflect the potential dilution of securities that could share in the Company's income (loss). The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share for the years ended December 31, 2017 and 2016. Outstanding stock options, warrants, unvested restricted common shares and other dilutive rights are not considered in the calculation, as the impact of the potential common shares (totaling approximately 2,555,580 shares and 1,093,750 shares for each of the years ended December 31, 2017 and 2016, respectively) would be anti-dilutive. For the year ended December 31, 2017 the dilutive rights not considered in the calculation, include shares of Series B Convertible Preferred Stock ("Series A Preferred Stock") outstanding that are convertible into 1,458,001 common shares. For periods when shares of preferred stock are outstanding, the two-class method is used to calculate basic and diluted earnings (loss) per common share since such preferred stock is a participating security under ASC 260 Earnings per Share. The two-class method is an earnings allocation formula that determines earnings per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. Under the two-class method, basic earnings (loss) per common share is computed by dividing net earnings (loss) attributable to common share after allocation of earnings to participating securities by the weighted-average number of shares of common stock outstanding during the year. Diluted earnings (loss) per common share, when applicable, is computed using the more dilutive of the two-class method or the if-converted method. In periods of net loss, no effect is given to participating securities since they do not contractually participate in the losses of the Company. Under the provisions of ASC 260, "Earnings Per Share," basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock and the dividends accumulated for the period on cumulative preferred stock from income from continuing operations. The impact of this computation during the year ended December 31, 2017 was de minimis.
Reclassification	Reclassification During 2017 depreciation and amortization was reclassed in the statement of operations as a separate line item. Expenses for the year ended December 31, 2016 have been reclassified to conform to the presentation. Selling, general and administrative expenses and research and development expenses for 2016 were reduced by $16,893 and $611,679, respectively, resulting in the presentation of $628,572 in depreciation and amortization expense for the year ended December 31, 2016. Depreciation and amortization expenses for 2016 included $535,256 of patent impairment charges.
Recently issued and adopted accounting pronouncements	Recently issued and adopted accounting pronouncements: The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company's consolidated financial statements properly reflect the change. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Leases (Topic 840) Leases (Topic 842) Land Easement Practical Expedient for Transition to Topic 842 In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, the FASB issued ASU No. 2017-11, "Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815)," which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

Organization and summary of s22

Organization and summary of significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Trading Securities	The composition of trading securities is as follows at December 31, 2017 and 2016: 2017 2016 Cost Fair Value Cost Fair Value Certificates of deposit / commercial paper $ — $ — $ 2,378,222 $ 2,373,891 Corporate bonds — — 5,138,182 5,132,870 Total trading securities $ — $ — $ 7,516,404 $ 7,506,761
Schedule of Investment Income	Investment income for the years ended December 31, 2017 and 2016 consists of the following: 2017 2016 Interest income $ 104,886 $ 126,296 Realized gains (losses) (21 ) (3,316 ) Unrealized gains (losses) 9,893 20,641 Management fee expenses (15,503 ) (21,897 ) Net investment income $ 99,255 $ 121,724
Schedule of Fair Value of Financial Instruments	Digital currencies financial assets measured at fair value on a recurring basis are summarized below and disclosed on the December 31, 2017, balance sheets as follows: Fair value measurement using Carrying value Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 41,651,965 $ 41,651,965 $ – $ – $ 41,651,965 Digital currencies $ 200,164 $ 200,164 $ – $ – $ 200,164 Convertible note receivable $ 200,000 $ – $ – $ 200,000 $ 200,000

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2017
Tess, Inc [Member]
Business Acquisition [Line Items]
Schedule of Assets and Liabilities Acquired	The following preliminary allocation of the purchase consideration is subject to revision as additional information becomes known in the future: Cash $ 198,000 Accounts receivable and prepaid expenses 9,000 In-process research and development 720,000 Goodwill 799,000 Accounts payable (21,000 ) Deferred income tax liability (186,000 ) Non-controlling interest (883,000 ) Purchase price $ 636,000
Schedule of Intangible rights acquired	Intangible rights acquired consisted of the following as of December 31, 2017: In-process research and development $ 720,000 Goodwill 799,000 Total 1,519,000 Less accumulated amortization — Net acquired intangibles $ 1,519,000
Kairos Global Technology, Inc [Member]
Business Acquisition [Line Items]
Schedule of Assets and Liabilities Acquired	The following is the allocation of the purchase consideration: Cash $ 1,131,000 Equipment 10,333,000 Accounts payable and accrued expenses (46,000 ) Deferred income tax liability (2,122,000 ) Purchase price $ 9,296,000
Schedule of Intangible rights acquired	Equipment rights acquired consisted of the following as of December 31, 2017 net of depreciation and impairment: Equipment $ 4,700,575 Less accumulated amortization (406,409 ) Net acquired equipment $ 4,294,166

Property and equipment (Tables)

Property and equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following as of December 31: 2017 2016 Crypto-currency machines $ 4,700,575 $ — Office and computer equipment 61,670 116,510 4,762,245 116,510 Less accumulated depreciation 468,079 110,972 $ 4,294,166 $ 5,538

Other long-term assets (Tables)

Other long-term assets (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Other Long-Term Assets	Beginning Balance Additions Impairments Ending Balance Year ended December 31, 2017: Cost: Patents $ 1,032,982 $ 26,850 $ — $ 1,059,832 Goodwill 447,951 799,257 — 1,247,208 Convertible Note Investment — 200,000 — 200,000 Total 1,480,933 1,026,107 — 2,507,040 Accumulated Amortization: Patents (482,183 ) (68,000 ) — (550,183 ) Goodwill (60,712 ) — — (60,712 ) Total (542,895 ) (68,000 ) — (610,895 ) Net Other Long-term Assets $ 938,038 $ 958,107 $ — $ 1,896,145 Year ended December 31, 2016: Cost: Patents $ 1,684,737 $ 26,067 $ (677,822 ) $ 1,032,982 Goodwill 447,951 — — 447,951 Total 2,132,688 26,067 (677,822 ) 1,480,933 Accumulated Amortization: Patents (548,327 ) (76,422 ) 142,566 (482,183 ) Goodwill (60,712 ) — — (60,712 ) Total (609,039 ) (76,422 ) 142,566 (542,895 ) Net Other Long-term Assets $ 1,523,649 $ (50,355 ) $ (535,256 ) $ 938,038

Stockholders' equity (Tables)

Stockholders' equity (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders Equity Tables
Schedule of Preferred Stock Activity	Following is a summary of Series A and Series B Preferred Stock activity for the year ended December 31, 2017: Series A Series B Total Preferred Stock Shares Amount Shares Amount Shares Amount Balance, January 1, 2017 — $ — — $ — $ — $ — Preferred stock issued upon notes payable conversion 19,194.72 4,798,671 — — 19,194.72 4,798,671 Preferred stock issued for Kairos acquisition 1,750,001.00 9,296,443 1,750,001.00 9,296,443 Series A Preferred stock converted to Common stock (19,194.72 ) (4,798,671 ) — — (19,194.72 ) (4,798,671 ) Series B Preferred stock converted to Common stock — — (292,000.00 ) (1,551,177 ) (292,000.00 ) (1,551,177 ) Balance, December 31, 2017 — $ — 1,458,001.00 $ 7,745,266 $ 1,458,001.00 $ 7,745,266

Stock options and warrants (Tab

Stock options and warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Recognized Stock-based Compensation	These expenses are included in the accompanying Statements of Operations for the years ended December 31, in the following categories: 2017 2016 Selling, general and administrative expenses $ 2,589,812 $ 542,989 Research and development expenses — 2,560 Total stock-based compensation $ 2,589,812 $ 545,549
Summary of Stock Restricted Plan Activity	A summary of the Company's restricted stock activity in the year ended December 31, 2017 is presented here: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2017 - $ - Granted 863,000 5.39 Vested (326,848 ) 4.79 Forfeited (40,000 ) 3.13 Unvested at December 31, 2017 496,152 $ 5.97
Schedule of Fair Value Assumptions Used to Estimate Stock-based Compensation	The Company currently provides stock-based compensation to employees, directors and consultants under the Plan. The Company utilized assumptions in the estimation of fair value of stock-based compensation for the years ended December 31, as follows: 2017 2016 Dividend yield 0 % 0 % Expected price volatility 95 to 15 % 99 to 100 % Risk free interest rate 1.92 to 1.99 % 1.20 to 1.83 % Expected term 5 years 5 years
Summary of Stock Incentive Plan Activity	A summary of stock option activity under the Plan for options to employees, officers, directors and consultants, for the year ended December 31, 2017, is presented below: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 2017 566,747 $ 20.46 Granted 120,000 9.00 Exercised (50,800 ) 2.94 Forfeited (516,414 ) 22.16 Outstanding at December 31, 2017 119,533 $ 9.02 9.8 $ 2,316,000 Exercisable at December 31, 2017 119,533 $ 9.02 9.8 $ 2,316,000
Schedule of Nonvested Share Activity	A summary of the activity of nonvested options under the Company's Plan to acquire common shares granted to employees, officers, directors and consultants during the year ended December 31, 2017 is presented below: Nonvested Shares Nonvested Shares Underlying Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Nonvested at January 1, 2017 97,738 $ 3.51 $ 2.58 Granted 120,000 9.00 4.25 Vested (160,738 ) 7.82 3.97 Forfeited (57,000 ) 2.92 2.16 Nonvested at December 31, 2017 — $ — $ —
Schedule of Nonqualified Award Activity	Following is a summary of outstanding options and warrants that were issued outside of the Plan for the year ended December 31, 2017: Shares Underlying Options / Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 2017 527,003 $ 13.36 Granted 4,451,113 17.03 Exercised for cash (620,000 ) 3.00 Exercised on a cashless basis (2,244,147 ) - Forfeited (169,074 ) 18.62 Outstanding at December 31, 2017 1,944,895 $ 35.06 2.7 $ 6,135,000 Exercisable at December 31, 2017 298,782 $ 7.87 2.7 $ 6,135,000

Animal Health License Agreeme28

Animal Health License Agreements (Tables)	12 Months Ended
	Dec. 31, 2017
Animal Health License Agreements [Abstract]
Schedule of Current and Long-Term Deferred Revenues	A tabular summary of the revenue categories and cumulative amounts of revenue recognition associated with the License Agreement follows: Category Totals License fees and milestone amounts paid / achieved $ 1,920,000 Third party obligations recorded, including WU (363,700 ) Deferred revenue balance 1,556,300 Revenue amortization to December 31, 2017 ($394,286 to December 31, 2016) (490,985 ) Net deferred revenue balance at December 31, 2017 ($1,162,014 to December 31, 2016) $ 1,065,315 Commencement of license fees revenue recognition Upon signing or receipt Commencement of milestone revenue recognition Upon milestone achievement over the then remaining life Original amortization period 197 months

Acquisition and Discontinued 29

Acquisition and Discontinued Operations (Tables) - BDI [Member]	12 Months Ended
	Dec. 31, 2017
Schedule of Assets and Liabilities Acquired	Under the acquisition method of accounting, the total estimated purchase consideration was allocated to the acquired tangible and intangible assets and assumed liabilities based on their estimated fair values as of the acquisition date. Following was the allocation of the purchase consideration: Cash and cash equivalents $ 17,000 Accounts receivable 21,000 Inventory 379,000 Prepaid and other assets 51,000 Equipment 1,000 Identifiable intangible assets: Trademarks (5 year estimated useful life) 99,000 Customer base (6 year estimated useful life) 37,000 Developed technology (4 year estimated useful life) 1,864,000 Total identifiable intangible assets 2,000,000 Goodwill 430,000 Accounts payable (118,000 ) Accrued and other liabilities (175,000 ) Non-controlling interest (29,000 ) Purchase price $ 2,577,000
Schedule of Intangible rights acquired	Intangible assets acquired consisted of the following as of December 31, 2016: Trademarks $ 99,000 Customer base 37,000 Developed technology 1,864,000 Total 2,000,000 Less accumulated amortization (148,264 ) Balance at December 31, 2016 $ 1,851,736
Schedule of Operation and Assets and Liabilities Related to Discontinued Operations	The Company's historical financial statements have been revised to present the operating results of the BDI business as a discontinued operation. Assets and liabilities related to the discontinued operations of BDI are approximately as follows as of December 31, 2017 and 2016: 2017 2016 Current assets: Accounts receivable $ - $ 5,000 Inventories - 416,000 Prepaid expenses - 66,000 Total current assets $ $ 487,000 Equipment and furnishings, net $ - $ 36,000 Intangible assets, net - 2,281,000 Deposit - 37,000 Total noncurrent assets $ - $ 2,354,000 Current liabilities: Accounts payable $ 16,000 $ 174,000 Accrued expenses 28,000 85,000 Deferred revenue 137,000 - Total current liabilities $ 181,000 $ 259,000 Summarized results of the discontinued operation are as follows for the years ended December 31, 2017 and 2016: 2017 2016 Sales $ 37,000 $ 9,000 Cost of sales 6,000 3,000 Gross margin 31,000 6,000 Operating expenses 955,000 1,121,000 Operating (loss) (924,000 ) (1,115,000 ) Escrow forfeiture gain 135,000 - Impairment (loss) (2,754,000 ) - (Loss) from discontinued operations $ (3,543,000 ) $ (1,115,000 )

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and (Liabilities)	The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2017 and 2016 are comprised of the following: As of December 31, 2017 2016 Deferred tax assets/(liabilities): Net operating loss carryforwards $ 25,837,000 $ 36,817,000 Research and development credit carryforwards 989,000 1,103,000 Stock option expense 252,000 - Property and equipment - 50,000 Capital loss carryforward - 444,000 Other 14,000 (22,000 ) Deferred tax asset 27,092,000 38,392,000 Valuation allowance (26,393,000 ) (38,392,000 ) Deferred income tax liability $ 699,000 $ -
Schedule of Federal Statutory Rate Reconcilition Tax Expense (Benefit)	The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows: For the years ended December 31, 2017 2016 Statutory federal income tax benefit (7,307,000 ) $ (1,453,000 ) State taxes, net of federal tax benefit (647,000 ) (128,000 ) Federal tax rate change and other adjustments 13,617,000 239,000 Stock compensation and other non-deductible expenses 3,118,000 - Change in valuation allowance (10,390,000 ) 1,342,000 Income taxes provision (benefit) $ (1,609,000 ) $ -

Organization and summary of s31

Organization and summary of significant accounting policies (Management's plans and basis of presentation) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 41,652,000
Working capital	41,350,000
Stockholders' equity	48,869,304	$ 14,920,359	$ 16,070,636
Accumulated deficit	$ 139,263,480	$ 109,855,276

Organization and summary of s32

Organization and summary of significant accounting policies (Principles of consolidation) (Details)	12 Months Ended
	Dec. 31, 2017
Kairos Global Technology, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Percentage owned	100.00%
Tess, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Percentage owned	52.00%
BiOptix Diagnostics, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Percentage owned	100.00%

Organization and summary of s33

Organization and summary of significant accounting policies (Cash, cash equivalents and short-term investments) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalent investment portfolio, percentage	100.00%	41.00%
Management fees	$ 15,503	$ 21,897

Organization and summary of s34

Organization and summary of significant accounting policies (Schedule of Trading Securities) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Trading Securities and Other Trading Assets [Line Items]
Trading securities cost, current		$ 7,516,404
Trading securities fair value, current		7,506,761
Certificates of deposit / commercial paper [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Trading securities cost, current		2,378,222
Trading securities fair value, current		2,373,891
Corporate Bonds [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Trading securities cost, current		5,138,182
Trading securities fair value, current		$ 5,132,870

Organization and summary of s35

Organization and summary of significant accounting policies (Schedule of Investment Income) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interest income	$ 104,886	$ 126,296
Realized gains (losses)	(21)	(3,316)
Unrealized gains (losses)	9,893	20,641
Management fee expenses	(15,503)	(21,897)
Net investment income	$ 99,255	$ 121,724

Organization and summary of s36

Organization and summary of significant accounting policies (Fair value of financial instruments) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Cash and cash equivalents	$ 41,651,965	$ 5,529,848	$ 2,012,283
Digital currencies	200,164
Convertible note receivable	200,000
Level 1 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Cash and cash equivalents	41,651,965
Digital currencies	200,164
Convertible note receivable
Level 2 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Cash and cash equivalents
Digital currencies
Convertible note receivable
Level 3 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Cash and cash equivalents
Digital currencies
Convertible note receivable	200,000
Carrying value [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Cash and cash equivalents	41,651,965
Digital currencies	200,164
Convertible note receivable	$ 200,000

Organization and summary of s37

Organization and summary of significant accounting policies (Property and equipment) (Details)	12 Months Ended
	Dec. 31, 2017
Crypto currency machine [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	2 years
Computer related assets [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years

Organization and summary of s38

Organization and summary of significant accounting policies (Impairment of long-lived assets) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Impairment of long-lived assets:
Impairment of crypto-currency machines	$ 5,218,000
Goodwill impairment
Impairment of finite lived intangible assets	$ 5,218,004	$ 535,256

Organization and summary of s39

Organization and summary of significant accounting policies (Income taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income taxes:
Unrecognized tax benefits
Accrued interest and penalties
Interest and penalties expense

Organization and summary of s40

Organization and summary of significant accounting policies (Income (loss) per share) (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income (loss) per share:
Shares not included in the computation of EPS	2,555,580	1,093,750
Series A Preferred Shares [Member]
Income (loss) per share:
Shares not included in the computation of EPS	1,458,001

Organization and summary of s41

Organization and summary of significant accounting policies (Reclassification) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Selling, general and administrative expenses	$ 7,293,593	$ 4,411,327
Research and development expenses	20,033	249,164
Depreciation and amortization expense	890,889	628,572
Patent impairment charges	$ 5,218,004
Reclassification [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Selling, general and administrative expenses		16,893
Research and development expenses		611,679
Depreciation and amortization expense		628,572
Patent impairment charges		$ 535,256

Acquisition (Narrative) (Detail

Acquisition (Narrative) (Details) - USD ($)	Nov. 03, 2017	Sep. 12, 2016	Feb. 21, 2018	Oct. 20, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Equity consideration issued for acquisition, number of shares		627,010
Value of equity consideration issued for acquisition						$ 636,750	$ 2,577,011
Loss attributable non-controlling interest amount						(125,059)
Impairment recognized						5,218,004
Equipment depreciation						$ 891,000	$ 4,000
Common Stock [Member]
Business Acquisition [Line Items]
Equity consideration issued for acquisition, number of shares						75,000	627,010
Value of equity consideration issued for acquisition						$ 636,750	$ 2,577,011
Kairos Global Technology, Inc [Member]
Business Acquisition [Line Items]
Impairment recognized						5,218,000
Royalty percentage	40.00%
Royalty amount	$ 1,000,000
Estimated average lives equipment	2 years
Equipment depreciation	$ 2,350,000
Kairos Global Technology, Inc [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Equity consideration issued for acquisition, number of shares			1,000,000
Aggregate cash consideration			$ 11,000,000
Kairos Global Technology, Inc [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Number of shares of common stock issuable upon conversion	1,750,001
Kairos Global Technology, Inc [Member] | Series B Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Common stock, par value	$ 5.31
Value of equity consideration issued for acquisition	$ 9,296,000
Stock issued for purchase of assets	1,750,001
Number of shares of common stock issuable upon conversion	292,000
Tess, Inc [Member]
Business Acquisition [Line Items]
Percentage of acquired entity				52.00%
Investment amount				$ 320,000
Stock issued during period				75,000
Common stock, par value				$ 8.49
Value of equity consideration issued for acquisition				$ 636,750
Percentage of non-controlling interest				48.00%
Purchased price				$ 883,000
Loss attributable non-controlling interest amount				125,000
Balance of non-controlling interest amount				$ 758,000
Purchase of consideration						$ 720,000
Percentage of discounted cash flows at a present value						60.00%
Tess, Inc [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Percentage of acquired entity					52.00%
Equity consideration issued for acquisition, number of shares					41,600,000
Tess, Inc [Member] | Restricted Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period				75,000
Tess, Inc [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Shares of subsidiary's common stock exchanged for company's restricted common stock				2,708,333
Number of common stock shares registered for resale through registration statement				25,000
Cresval [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Equity consideration issued for acquisition, number of shares					80,000,000
Shareholders [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Equity consideration issued for acquisition, number of shares					8,400,000

Acquisition (Schedule of Assets

Acquisition (Schedule of Assets and Liabilities Acquired) (Details) - USD ($)	Dec. 31, 2017	Nov. 03, 2017	Oct. 20, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 1,186,496			$ 387,239
Tess, Inc [Member]
Business Acquisition [Line Items]
Cash			$ 198,000
Accounts receivable and prepaid expenses			9,000
In-process research and development	720,000		720,000
Goodwill	799,000		799,000
Accounts payable			(21,000)
Non-controlling interest			(883,000)
Deferred income tax liability			(186,000)
Purchase price			$ 636,000
Kairos Global Technology, Inc [Member]
Business Acquisition [Line Items]
Cash		$ 1,131,000
Equipment	$ 4,700,575	10,333,000
Accounts payable		(46,000)
Deferred income tax liability		(2,122,000)
Purchase price		$ 9,296,000

Acquisition (Schedule of Intang

Acquisition (Schedule of Intangible Rights Acquired) (Details) - USD ($)	Dec. 31, 2017	Nov. 03, 2017	Oct. 20, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 1,186,496			$ 387,239
Total				2,000,000
Less accumulated amortization				(148,264)
Net acquired intangibles				$ 1,851,736
Tess, Inc [Member]
Finite-Lived Intangible Assets [Line Items]
In-process research and development	720,000		$ 720,000
Goodwill	799,000		$ 799,000
Total	1,519,000
Less accumulated amortization
Net acquired intangibles	1,519,000
Kairos Global Technology, Inc [Member]
Finite-Lived Intangible Assets [Line Items]
Equipment	4,700,575	$ 10,333,000
Less accumulated amortization	(406,409)
Net acquired intangibles	$ 4,294,166

Property and equipment (Narrati

Property and equipment (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 25, 2016	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Sales price of corporate headquarters, land and building to a third party	$ 4,053,000
Gain on sale of property and equipment	1,943,000	$ (3,639)	$ 1,942,980
Proceeds from sale of property and equipment	$ 1,809,000		$ 1,808,787
Accumulated depreciation relating to impairment loss written off		414,581
Accumulated depreciation relating to other equipment written off		$ 51,201

Property and equipment (Schedul

Property and equipment (Schedule of Property and Equipment) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment	$ 4,762,245	$ 116,510
Less accumulated depreciation	468,079	110,972
Total property and equipment, net	4,294,166	5,538
Depreciation expense	891,000	4,000
Crypto currency machine [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	4,700,575
Office and computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 61,670	$ 116,510

Investment in goNumerical (Deta

Investment in goNumerical (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 28, 2018
Coninsquare [Member] | Warrant [Member]
Percentage of minority interest	14.70%
Maturity date	May 30, 2018
Coinsquarel [Member]
Minority interest	$ 3,000,000
Percentage of minority interest	10.90%
Coinsquarel [Member] | Subsequent Event [Member]
Amount of Investment		$ 6,400,000
Equity investment		2,800,000
Financing amount		24,000,000
Warrant acquired cash payment		$ 3,600,000
Percentage of owned		12.90%

Other long-term assets (Narrati

Other long-term assets (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Future amortization
2,018		$ 60,000
2,019		60,000
2,020		60,000
2,021		60,000
2,022		60,000
Amortization expense of intangible assets
Patent impairment charges		5,218,004	535,256
Convertible note		200,000
Patents [Member]
Future amortization
Amortization expense of intangible assets		$ 68,000	$ 76,422
Verady, LLC [Member]
Future amortization
Convertible note	$ 200,000
Maturity date	Dec. 31, 2022
Interest rate	6.00%

Other long-term assets (Schedul

Other long-term assets (Schedule of Other Long-Term Assets) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Patents:
Cost, beginning	$ 550,799
Cost, ending	509,649	$ 550,799
Additions
Goodwill:
Goodwill, beginning	447,951	447,951
Additions	799,257
Impairments
Goodwill, ending	1,247,208	447,951
Accumulated amortization, beginning	(60,712)	(60,712)
Additions
Impairments
Accumulated amortization, ending	(60,712)	(60,712)
Convertible Note Investment:
Convertible Note Investment
Additions	200,000
Impairments
Convertible Note Investment , ending	200,000
Total other long-term assets:
Cost, beginning	1,480,933	2,132,688
Additions	1,026,107	26,067
Impairments		(677,822)
Cost, ending	2,507,040	1,480,933
Total accumulated amortization of intangible assets and goodwill	(610,895)	(542,895)
Other long-term assets, net, beginning	938,038	1,523,649
Additions	958,107	(50,355)
Impairments	(5,218,004)
Other long-term assets, net, ending	1,896,145	938,038
Patents [Member]
Patents:
Cost, beginning	1,032,982	1,684,737
Additions	26,850	26,067
Impairment		(677,822)
Cost, ending	1,059,832	1,032,982
Accumulated amortization, beginning	(482,183)	(548,327)
Additions	(68,000)	(76,422)
Impairments		142,566
Accumulated amortization, ending	$ (550,183)	$ (482,183)

Notes and Other Obligations (Na

Notes and Other Obligations (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Notes Payable	$ 135,574	$ 139,611
Fixed interest rate	4.50%
Interest expense	$ 4,806,637	$ 30,161
Mortgage Notes [Member]
Debt Instrument [Line Items]
Amortization period		15 years
Balloon maturity period		5 years
Mortgage Notes [Member] | Commercial Banks [Member]
Debt Instrument [Line Items]
Fixed interest rate		3.95%
Mortgage Notes [Member] | U.S. Small Business Administration [Member]
Debt Instrument [Line Items]
Fixed interest rate		5.86%
Private Placement [Member]
Debt Instrument [Line Items]
Maturity date		Mar. 30, 2020
Private Placement [Member] | Warrant [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock	1,900,000
Exercise price	$ 3.56
Maturity date	Mar. 15, 2020
Private Placement [Member] | Convertible Note [Member]
Debt Instrument [Line Items]
Fixed interest rate	2.00%
Conversion price	$ 2.50
Proceeds from convertible debt held in escrow	$ 4,750,000
Interest expense	$ 48,671
Issuance date	Mar. 16, 2017
Maturity date	Sep. 16, 2018

Stockholders' equity (Narrative

Stockholders' equity (Narrative) (Details) - USD ($)	Nov. 03, 2017	Oct. 10, 2017	Sep. 12, 2016	Dec. 31, 2017	Oct. 20, 2017	Oct. 18, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Oct. 02, 2017	Sep. 20, 2017	Aug. 21, 2017	Aug. 20, 2017
Class of Stock [Line Items]
Restricted common shares issued for services, value								$ 2,589,812	$ 545,549
Proceeds from issuance of common stock								38,451,052
Discount on Convertible Debt arising from values of beneficial conversion feature								2,424,849
Discount on Convertible Debt arising from values of warrants								$ 2,325,151
Common stock, shares authorized				170,000,000				170,000,000	60,000,000			170,000,000	60,000,000
Preferred stock, shares authorized				15,000,000				15,000,000	0
Interest rate percentage				4.50%				4.50%
Interest expense								$ 4,806,637	$ 30,161
Cash dividend						$ 9,562,000		9,562,331
Dividends paid, price per share										$ 1
Proceeds from warrant exercise							$ 350,000	1,860,000
Private placement of Common Stock								$ 36,537,543
Common stock issued for acquisition, shares			627,010
2002 Stock Incentive Plan [Member]
Class of Stock [Line Items]
Rights forfeited								515,578
Nonqualified [Member]
Class of Stock [Line Items]
Number of common shares hold by warrant holders								2,244,147
Shares issued of common stock in exchange for termination of warrants								1,335,408
Proceeds from warrant exercise								$ 1,860,000
Stock Incentive Plan [Member]
Class of Stock [Line Items]
Common shares vested								160,738
Dividend yield								0.00%	0.00%
Expected term								5 years	5 years
Expected price volatility, minimum								95.00%	99.00%
Expected price volatility, maximum								15.00%	100.00%
Risk free interest rates, minimum								1.92%	1.20%
Risk free interest rates, maximum								1.99%	1.83%
Common Stock [Member]
Class of Stock [Line Items]
Restricted common shares issued for services								174,082
Restricted common shares issued for services, value								$ 2,589,812	$ 545,549
Discount on Convertible Debt arising from values of beneficial conversion feature								2,424,849
Discount on Convertible Debt arising from values of warrants								$ 2,325,151
Preferred Stock issued upon Notes payable conversion, shares
Private placement of Common Stock								$ 36,537,543
Common stock issued for acquisition, shares								75,000	627,010
KairosGlobalTechnologyIncMember | Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued for purchase of assets	1,750,001
Number of shares of common stock issuable upon conversion	292,000
Preferred stock outstanding	1,458,001
KairosGlobalTechnologyIncMember | Common Stock [Member]
Class of Stock [Line Items]
Conversion price	$ 6.80
Preferred stock stated value per share	$ 6.80
Number of shares of common stock issuable upon conversion	1,750,001
BDI [Member]
Class of Stock [Line Items]
Number of common shares previously held in escrow, cancelled during period								32,801
Estimated value of common shares recoded resulting in a reduction in impairment loss								$ 134,812
Share price				$ 4.11				$ 4.11
Tess, Inc [Member]
Class of Stock [Line Items]
Issuance of common stock					75,000
Resale of shares					25,000
Private Placement [Member]
Class of Stock [Line Items]
Total amount of financing from common stock units				$ 2,250,000				$ 2,250,000
Proceeds from issuance of common stock								$ 1,000,000
Issuance of common stock								400,000
Offering expenses incurred from private placement stock issuance								$ 336,491
Common stock shares held in escrow				500,000				500,000
Proceeds from common stock and warrants released								$ 1,250,000
Purchase price				$ 2.50				$ 2.50
Conversion of notes payable and accrued interest to preferred stock								$ 4,798,671
Maturity date									Mar. 30, 2020
Private Placement [Member] | Warrant [Member]
Class of Stock [Line Items]
Number of warrants issued								900,000
Exercise price				$ 3.56				$ 3.56
Warrants to purchase common stock				1,900,000				1,900,000
Warrant to purchase term								3 years
Rights forfeited								553,911
Total consideration under the agreements forfeited during period								$ 399,513
Total consideration under the agreements forfeited during period charged to equity								392,007
Total consideration under the agreements forfeited during period recorded as compensation								$ 7,506
Fair value of warrants							$ 2,114,000
Dividend yield							0.00%	0.00%
Expected term							3 years	3 years
Expected price volatility							114.00%	108.00%
Risk free interest rate							1.66%	1.47%
Expected price volatility, minimum							49.00%
Expected price volatility, maximum							99.00%
Risk free interest rates, minimum							0.80%
Risk free interest rates, maximum							2.30%
Maturity date								Mar. 15, 2020
Private Placement [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of common stock								900,000
Purchase price				$ 3.50				$ 3.50
Private Placement [Member] | Convertible Note [Member]
Class of Stock [Line Items]
Debt instrument face amount				$ 4,750,000				$ 4,750,000
Conversion price				$ 2.50				$ 2.50
Conversion of note principal balance								$ 4,750,000
Conversion of accrued interest on note								48,671
Conversion of notes payable and accrued interest to preferred stock								$ 4,798,671
Number of common share preferred holders have rights to											1,919,472
Interest rate percentage				2.00%				2.00%
Interest expense								$ 48,671
Interest expense recognized on conversion of convertible notes								$ 4,750,000
Maturity date								Sep. 16, 2018
May 2013 private offering [Member] | Nonqualified [Member]
Class of Stock [Line Items]
Issuance of common stock								106,719
Exercise price				$ 10.88				$ 10.88
Shares surrendered for issuance of common stock								184,147
March 2017 private offering [Member] | Nonqualified [Member]
Class of Stock [Line Items]
Issuance of common stock								214,851
Exercise price				3.50				$ 3.50
Shares surrendered for issuance of common stock								360,000
March 2017 private offering of convertible notes [Member] | Nonqualified [Member]
Class of Stock [Line Items]
Issuance of common stock								1,013,838
Shares surrendered for issuance of common stock								1,700,000
March 2017 private offering of convertible notes [Member] | Stock Incentive Plan [Member]
Class of Stock [Line Items]
Exercise price				3.56				$ 3.56
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock issued upon Notes payable conversion, shares
Conversion of stock shares converted into common stock								619,518
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock issued upon Notes payable conversion, shares								19,194.72
Series A Preferred Stock [Member] | Private Placement [Member]
Class of Stock [Line Items]
Preferred Stock issued upon Notes payable conversion, shares								19,195
Preferred stock stated value per share				$ 250				$ 250
Number of common share preferred holders have rights to				1,919,472				1,919,472
Designated as 2% Series A Convertible Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized				2,000,000				2,000,000
0% Convertible Preferred Stock Series B [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	1,750,001			1,750,001				1,750,001	0
Preferred stock outstanding				1,458,001				1,458,001	0
Restricted Stock [Member]
Class of Stock [Line Items]
Common shares vested								326,848
Rights forfeited								833
Restricted Stock [Member] | Consultant [Member]
Class of Stock [Line Items]
Restricted common shares issued for services				3,215				138,067
Restricted common shares issued for services, value								$ 1,178,200
Restricted Stock [Member] | Directors and Officers [Member]
Class of Stock [Line Items]
Award of restricted shares								863,000
Shares terminated								40,000
Common shares vested								326,848
Issuance of common stock								174,082
Non-qualified stock option awards [Member]
Class of Stock [Line Items]
Rights forfeited								37,500
Temporary Reduction in Warrant Exercise Price [Member]
Class of Stock [Line Items]
Amended exercise price of warrants		$ 3
Total warrants covered by amended exercise price		2,800,000
Total warrants exercised for cash during amendment period		620,000
Proceeds from warrant exercise		$ 1,860,000
Private Placement [Member]
Class of Stock [Line Items]
Issuance of common stock				1,646,113
Purchase price				$ 40				$ 40
Exercise price				$ 40				$ 40
Warrants to purchase common stock				1,646,113				1,646,113
Private placement of Common Stock				$ 36,537,543
Offering expense				$ 500,000

Stockholders' equity (Schedule

Stockholders' equity (Schedule of Preferred Stock Activity) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
BALANCE	$ 14,920,359	$ 16,070,636
Preferred Stock issued upon Notes payable conversion	4,798,671
Preferred stock issued for Kairos acquisition	$ 8,296,443
Series A Preferred stock converted to Common stock, shares	6,349,848
BALANCE	$ 48,869,304	$ 14,920,359
Series A Preferred Stock [Member]
BALANCE
BALANCE, shares
Preferred Stock issued upon Notes payable conversion	$ 4,798,671
Preferred Stock issued upon Notes payable conversion, shares	19,194.72
Series A Preferred stock converted to Common stock	$ (4,798,671)
Series A Preferred stock converted to Common stock, shares	(19,194.72)
Series B Preferred stock converted to Common stock
Series B Preferred stock converted to Common stock, shares
BALANCE
BALANCE, shares
Series B Preferred Stock [Member]
BALANCE
BALANCE, shares
Preferred Stock issued upon Notes payable conversion
Preferred Stock issued upon Notes payable conversion, shares
Preferred stock issued for Kairos acquisition	$ 9,296,443
Preferred stock issued for Kairos acquisition, shares	1,750,001
Series A Preferred stock converted to Common stock
Series A Preferred stock converted to Common stock, shares
Series B Preferred stock converted to Common stock	$ (1,551,177)
Series B Preferred stock converted to Common stock, shares	(292,000)
BALANCE	$ 7,745,266
BALANCE, shares	1,458,001
Preferred Stock [Member]
BALANCE
BALANCE, shares
Preferred Stock issued upon Notes payable conversion	$ 4,798,671
Preferred Stock issued upon Notes payable conversion, shares	19,194.72
Preferred stock issued for Kairos acquisition	$ 9,296,443
Preferred stock issued for Kairos acquisition, shares	1,750,001
Series A Preferred stock converted to Common stock	$ (4,798,671)
Series A Preferred stock converted to Common stock, shares	(19,194.72)
Series B Preferred stock converted to Common stock	$ (1,551,177)
Series B Preferred stock converted to Common stock, shares	(292,000)
BALANCE	$ 7,745,266
BALANCE, shares	1,458,001

Stock options and warrants (Sto

Stock options and warrants (Stock Incentive Plan Options) (Narrative) (Details) - USD ($)	1 Months Ended				12 Months Ended
	Mar. 31, 2018	Jan. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved under the Plan			895,000		895,000
Fair value of options vested					$ 4,654,000
Proceeds from options exercised					149,136
Net proceeds from exercise of stock options					149,136
Total stock-based compensation					2,589,812	545,549
Warrants issued				100,000
Proceeds from exercise of warrants				$ 350,000	$ 1,860,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period					3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period					5 years
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					120,000
Common shares vested					160,738
Options granted, exercise price					$ 9
Options grant date fair value					$ 4.25
Options exercised					50,800
Options forfeited					516,414
Options forfeited, exercise price					$ 22.16
Options forfeited, unvested, exercise price					$ 2.92
Fair value of options vested					$ 639,000	$ 646,000
Shares issued in options exercised					50,800
Net proceeds from exercise of stock options					$ 149,136
Total intrinsic value when exercised					$ 171,000
Unrecognized compensation cost, period for recognition					1 year
Stock Incentive Plan [Member] | Directors and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					120,000
Options granted, exercise price					$ 9
Stock Incentive Plan [Member] | Vesting in Period One [Member] | Directors and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					20,000
Options granted, exercise price					$ 4.02
Vesting period					24 months
Stock Incentive Plan [Member] | Vesting in Period Two [Member] | Directors and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					100,000
Options granted, exercise price					$ 10
Vested Options [Member] | Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options forfeited					459,414	21,859
Options forfeited, exercise price					$ 24.55	$ 40.49
Vested Options [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued in options exercised		19,533
Proceeds from options exercised		$ 78,523
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					863,000
Common shares vested					326,848
Options grant date fair value					$ 5.39
Options forfeited					40,000
Fair value of options vested					$ 125,000
Expected to vest			326,848		326,848
Unrecognized compensation cost			$ 2,964,000		$ 2,964,000
Unrecognized compensation cost, period for recognition					1 year
Rights forfeited					833
Total stock-based compensation					$ 1,714,116
Vested rights remaining to be issued					152,766
Restricted Stock [Member] | Certain board members and officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					292,500
Restricted Stock [Member] | Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					863,000
Options forfeited					6,251
Restricted Stock [Member] | Advisory Board member [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options forfeited					20,000
Restricted Stock [Member] | Directors and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares vested					326,848
Restricted Stock [Member] | Vested in Period [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options vested					$ 1,565,000
Restricted Stock [Member] | 2017 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					157,000
Restricted Stock [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares vested	50,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period					10 years
Total stock-based compensation					$ 767,675
Stock Options [Member] | 2017 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					91,333
Other Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation					$ 108,021
Equity rights terminations [Member] | Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options forfeited					515,578
Options terminated [Member] | Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options forfeited					836
Unvested Options [Member] | Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options forfeited					57,000	3,620
Options forfeited, unvested, exercise price					$ 2.92	$ 15.13
May 2013 private offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued for surrendered for issuance of common stock			3,215

Stock options and warrants (Oth

Stock options and warrants (Other Common Stock Purchase Options and Warrants) (Narrative) (Details) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, operating expense			$ 2,589,812	$ 545,549
Proceeds from issuance of common stock			38,451,052
Proceeds from warrants exercised		$ 350,000	1,860,000
Private Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from private placement		$ 7,000,000	37,000,000
Proceeds from issuance of common stock			$ 1,000,000
Expiration date		Mar. 31, 2020	Dec. 31, 2020
Common shares issued			400,000
Nonqualified [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards outstanding	1,944,895		1,944,895	527,003
Options granted	1,646,113	2,800,000	4,451,113
Options granted, exercise price	$ 40	$ 3.50	$ 17.03
Options forfeited			169,074
Lapsed shares			60,000
Number of lapsed options vested			15,000
Number of lapsed options unvested			45,000
Expired options			71,574
Remaining forfeited options			37,500
Proceeds from warrants exercised			$ 1,860,000
Number of warrants exercised			620,000
Warrants issued price per share			$ 3
Number of common shares hold by warrant holders			2,244,147
Shares issued of common stock in exchange for termination of warrants			1,335,408
Nonqualified [Member] | Compensatory Arrangements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	3.78		$ 3.78
Nonqualified [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted				95,000
Share-based compensation, operating expense			$ 88,620	$ 56,000
Options forfeited				95,000
Nonqualified [Member] | Warrants Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted		900,000
Options granted, exercise price		$ 3.50
Nonqualified [Member] | Warrants Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted		1,900,000
Options granted, exercise price		$ 3.56
Nonqualified [Member] | May 2013 private offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	10.88		$ 10.88
Shares surrendered for issuance of common stock			184,147
Common shares issued			106,719
Nonqualified [Member] | March 2017 private offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 3.50		$ 3.50
Shares surrendered for issuance of common stock			360,000
Common shares issued			214,851
Nonqualified [Member] | March 2017 private offering of convertible notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares surrendered for issuance of common stock			1,700,000
Common shares issued			1,013,838
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards outstanding	119,533		119,533	566,747
Options granted			120,000
Options granted, exercise price			$ 9
Unvested exercise price				$ 2.58
Stock Incentive Plan [Member] | March 2017 private offering of convertible notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 3.56		$ 3.56

Stock options and warrants (Sch

Stock options and warrants (Schedule of Stock-based Compensation) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 2,589,812	$ 545,549
Selling, general and administrative expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	2,589,812	542,989
Research and development expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation		$ 2,560

Stock options and warrants (S56

Stock options and warrants (Schedule of Restricted Stock Activity) (Details) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Number of shares
Beginning balance | shares
Granted | shares	863,000
Vested | shares	(326,848)
Forfeited | shares	(40,000)
Ending balance | shares	496,152
Weighted Average Grant Date Fair value
Beginning balance | $ / shares
Granted | $ / shares	5.39
Vested | $ / shares	4.79
Forfeited | $ / shares	3.13
Ending balance | $ / shares	$ 5.97

Stock options and warrants (S57

Stock options and warrants (Schedule of Fair Value Assumptions) (Details) - Stock Incentive Plan [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected price volatility, minimum	95.00%	99.00%
Expected price volatility, maximum	15.00%	100.00%
Risk free interest rate, minimum	1.92%	1.20%
Risk free interest rate, maximum	1.99%	1.83%
Expected term	5 years	5 years

Stock options and warrants (S58

Stock options and warrants (Schedule of Award Activity) (Details) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2017
Stock Incentive Plan [Member]
Shares Underlying Options
Outstanding, beginning			566,747
Granted			120,000
Exercised for cash			(50,800)
Forfeited			(516,414)
Outstanding, ending	119,533		119,533
Exercisable	119,533		119,533
Weighted Average Exercise Price
Outstanding, beginning			$ 20.46
Granted			9
Exercised for cash			2.94
Forfeited			22.16
Outstanding, ending	$ 9.02		9.02
Exercisable	$ 9.02		$ 9.02
Weighted Average Remaining Contractual Term
Outstanding			9 years 9 months 18 days
Exercisable			9 years 9 months 18 days
Aggregate Intrinsic Value
Outstanding	$ 2,316,000		$ 2,316,000
Exercisable	$ 2,316,000		$ 2,316,000
Nonqualified [Member]
Shares Underlying Options
Outstanding, beginning			527,003
Granted	1,646,113	2,800,000	4,451,113
Exercised for cash			(620,000)
Exercised on a cashless basis			(2,244,147)
Forfeited			(169,074)
Outstanding, ending	1,944,895		1,944,895
Exercisable	298,782		298,782
Weighted Average Exercise Price
Outstanding, beginning			$ 13.36
Granted	$ 40	$ 3.50	17.03
Exercised for cash			3
Exercised on a cashless basis
Forfeited			18.62
Outstanding, ending	35.06		35.06
Exercisable	$ 7.87		$ 7.87
Weighted Average Remaining Contractual Term
Outstanding			2 years 8 months 12 days
Exercisable			2 years 8 months 12 days
Aggregate Intrinsic Value
Outstanding	$ 6,135,000		$ 6,135,000
Exercisable	$ 6,135,000		$ 6,135,000

Stock options and warrants (S59

Stock options and warrants (Schedule of Nonvested Awards) (Details) - Stock Incentive Plan [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Nonvested Shares Underlying Options
Beginning balance | shares	97,738
Granted | shares	120,000
Vested | shares	(160,738)
Forfeited | shares	(57,000)
Ending balance | shares
Weighted Average Exercise Price
Beginning balance	$ 3.51
Granted	9
Vested	7.82
Forfeited	2.92
Ending balance
Weighted Average Grant Date Fair Value
Beginning balance	2.58
Granted	4.25
Vested	3.97
Forfeited	2.16
Ending balance

Animal Health License Agreeme60

Animal Health License Agreements (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Animal Health License Agreements [Abstract]
Annual royalty commitment	$ 20,000
Portion of license fees and royalties received from sublicensing agreements, owed to Washington University	$ 10,000
Prior written notice period for termination of license agreement by the licensee	180 days
Aggregate milestone payments, maximum	$ 1,100,000
Additional milestone payments, maximum	2,000,000
Original amount of deferred revenue	1,556,300
Deferred revenue	96,698	$ 96,698
Deferred revenue, noncurrent	968,617	1,065,316
Recognition of license fee revenue	$ 96,698	$ 96,699

Animal Health License Agreeme61

Animal Health License Agreements (Schedule of Revenue Recognition Associated with the License Agreement) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Animal Health License Agreements [Abstract]
License fees and milestone amounts paid / achieved	$ 1,920,000
Third party obligations recorded, including WU	(363,700)
Deferred revenue balance	1,556,300
Revenue recognized	(490,985)	$ 394,286
Deferred revenue	$ 1,065,315	$ 1,162,014
Original amortization period	197 months

Acquisition and Discontinued 62

Acquisition and Discontinued Operations (Narrative) (Details) - USD ($)	Sep. 12, 2016	Sep. 12, 2016	Nov. 30, 2016	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Equity consideration issued for acquisition, number of shares		627,010
Value of equity consideration issued for acquisition					$ 636,750	$ 2,577,011
Net loss					19,845,873	4,272,837
Impairment loss on Goodwill
BDI [Member]
Business Acquisition [Line Items]
Percentage of outstanding voting stock owned by parent	98.00%	98.00%
Aggregate cash consideration			$ 29,000
Percentage of Venaxis common stock issued as equity consideration	14.00%	14.00%
Total Revenue				$ 174,000
Net loss				$ 2,102,000
Loss per share (Basic and Diluted)				$ 0.47
Impairment loss on Inventory					453,000
Impairment loss on Goodwill					430,000
Impairment loss of Equipment and furnishings					29,000
Impairment loss of Intangible Assests					1,833,000
Impairment loss on other items					$ 9,000
Inventories acquired						416,000
Inventories raw materials acquired						188,000
Inventories finished goods acquired						$ 228,000
BDI [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Equity consideration issued for acquisition, number of shares	627,010
Value of equity consideration issued for acquisition	$ 2,577,000

Acquisition and Discontinued 63

Acquisition and Discontinued Operations (Schedule of Assets and Liabilities Acquired) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Identifiable intangible assets:
Identifiable intangible assets			$ 2,000,000
Goodwill		$ 1,186,496	387,239
Estimated useful life		197 months
Trademarks [Member]
Identifiable intangible assets:
Identifiable intangible assets			99,000
Customer base [Member]
Identifiable intangible assets:
Identifiable intangible assets			37,000
Developed technology [Member]
Identifiable intangible assets:
Identifiable intangible assets			$ 1,864,000
BDI [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	$ 17,000
Accounts receivable	21,000
Inventory	379,000
Prepaid and other assets	51,000
Equipment	1,000
Identifiable intangible assets:
Identifiable intangible assets	2,000,000
Goodwill	430,000
Accounts payable	(118,000)
Accrued and other liabilities	(175,000)
Non-controlling interest	(29,000)
Purchase price	2,577,000
BDI [Member] | Trademarks [Member]
Identifiable intangible assets:
Identifiable intangible assets	$ 99,000
Estimated useful life	5 years
BDI [Member] | Customer base [Member]
Identifiable intangible assets:
Identifiable intangible assets	$ 37,000
Estimated useful life	6 years
BDI [Member] | Developed technology [Member]
Identifiable intangible assets:
Identifiable intangible assets	$ 1,864,000
Estimated useful life	4 years

Acquisition and Discontinued 64

Acquisition and Discontinued Operations (Schedule of Intangible Assets Acquired) (Details)	Dec. 31, 2016USD ($)
Finite-Lived Intangible Assets [Line Items]
Total	$ 2,000,000
Less accumulated amortization	(148,264)
Net acquired intangibles	1,851,736
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Total	99,000
Customer base [Member]
Finite-Lived Intangible Assets [Line Items]
Total	37,000
Developed technology [Member]
Finite-Lived Intangible Assets [Line Items]
Total	$ 1,864,000

Acquisition and Discontinued 65

Acquisition and Discontinued Operations (Schedule of Assets and Liabilities related to Discontinued Operations) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Total current assets	$ 44	$ 486,890
Current liabilities:
Total current liabilities	181,340	258,819
BDI [Member]
Current assets:
Accounts receivable		5,000
Inventories		416,000
Prepaid expenses		66,000
Total current assets		487,000
Equipment and furnishings, net		36,000
Intangible assets, net		2,281,000
Deposit		37,000
Total noncurrent assets		2,354,000
Current liabilities:
Accounts payable	16,000	174,000
Accrued expenses	28,000	85,000
Deferred revenue	137,000
Total current liabilities	$ 181,000	$ 259,000

Acquisition and Discontinued 66

Acquisition and Discontinued Operations (Summarized results of the discontinued operation) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Escrow forfeiture gain	$ 134,812
Impairment (loss)	(2,754,131)
BDI [Member]
Sales	37,000	9,000
Cost of sales	6,000	3,000
Gross margin	31,000	6,000
Operating expenses	955,000	1,121,000
Operating (loss)	(924,000)	(1,115,000)
Escrow forfeiture gain	135,000
Impairment (loss)	(2,754,000)
(Loss) from discontinued operations	$ (3,543,000)	$ (1,115,000)

Income taxes (Narrative) (Detai

Income taxes (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Income tax benefit		$ (1,609,000)
Corporate tax rate	21.00%
Decrease deferred tax assets		14,000,000
Deferred tax liability		2,308,000
Net operating loss carry forwards		$ 105,000,000
Net operating loss carry forwards, expiration date		Dec. 31, 2037
Decrease in deferred tax asset valuation allowance		$ 94,000,000
Deferred tax assets from discontinued operations		$ 900,000
Minimum [Member]
Operating Loss Carryforwards [Line Items]
Corporate tax rate		21.00%
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Corporate tax rate		34.00%

Income taxes (Schedule of Defer

Income taxes (Schedule of Deferred Tax Assets and (Liabilities)) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 25,837,000	$ 36,817,000
Research and development credit carryforwards	989,000	1,103,000
Stock option expense	252,000
Property and equipment		50,000
Capital loss carryforward		444,000
Other	14,000	(22,000)
Deferred tax asset	27,092,000	38,392,000
Valuation allowance	(26,393,000)	(38,392,000)
Deferred income tax liability	$ 699,000

Income taxes (Reconciliation of

Income taxes (Reconciliation of Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Statutory federal income tax benefit	$ (7,307,000)	$ (1,453,000)
State taxes, net of federal tax benefit	(647,000)	(128,000)
Federal tax rate change and other adjustments	13,617,000	239,000
Stock compensation and other non-deductible expenses	3,118,000
Change in valuation allowance	(10,390,000)	1,342,000
Income taxes provision (benefit)	$ (1,609,000)

Commitments and contingencies (

Commitments and contingencies (Details)	1 Months Ended	12 Months Ended
	Feb. 25, 2016USD ($)	Dec. 31, 2017USD ($)Officers	Dec. 31, 2016USD ($)	May 31, 2017USD ($)
Operating Leased Assets [Line Items]
Rent expense		$ 23,000
Sales price of corporate headquarters, land and building to a third party	$ 4,053,000
Proceeds from sale of property plant and equipment	1,809,000		$ 1,808,787
Gain from sale of property plant and equipment	$ 1,943,000	$ (3,639)	1,942,980
Employment Contracts [Member]
Operating Leased Assets [Line Items]
Number of officers | Officers		2
Annual commitment amount		$ 572,000
Subsidiary [Member]
Operating Leased Assets [Line Items]
Rent expense		$ 239,000	120,000
BDI [Member]
Operating Leased Assets [Line Items]
Lease expiration date		Mar. 31, 2018
Future minimum operating lease commitments owed in 2017				$ 294,000
Rent expense		$ 216,000	$ 92,000
Prepayment of rent				$ 80,419
Lease deposit		$ 37,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2017
Two shareholders [Member]
Related Party Transaction [Line Items]
Ownership Percentage		10.00%
Barry Honig [Member]
Related Party Transaction [Line Items]
Ownership Percentage		11.20%
Proceeds from Private Placement offering	$ 1,750,000	$ 500,000
Ms. DeFrancesco [Member]
Related Party Transaction [Line Items]
Ownership Percentage		11.45%
Proceeds from Private Placement offering		$ 360,000
GRQ Consultants, Inc [Member]
Related Party Transaction [Line Items]
Cash payment received by Mr. Honig		$ 50,000
Percentage share of Kairos owned by Mr. Honig [Member]
Related Party Transaction [Line Items]
Ownership Percentage		8.60%
Percentage share of Kairos owned by Ms. DeFrancesco [Member]
Related Party Transaction [Line Items]
Ownership Percentage		6.30%

Subsequent Events (Details)

Subsequent Events (Details)	Apr. 09, 2018USD ($)	Sep. 12, 2016shares	Mar. 27, 2018USD ($)	Mar. 26, 2018USD ($)	Feb. 27, 2018USD ($)	Feb. 21, 2018USD ($)shares	Jan. 31, 2018USD ($)	Dec. 31, 2017	Nov. 30, 2017
Subsequent Event [Line Items]
Equity consideration issued for acquisition, number of shares | shares		627,010
Percentage shares of Prive owned by Mr. Michael Ho [Member]
Subsequent Event [Line Items]
Ownership percentage								24.80%
Percentage shares of Prive owned by Mr. Bryan Pascal [Member]
Subsequent Event [Line Items]
Ownership percentage								18.40%
Marshals Service [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of bitcoins acquired							500
Acquired amount of bitcoins							$ 5,625,000
Kairos Global Technology, Inc [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate cash consideration						$ 11,000,000
Equity consideration issued for acquisition, number of shares | shares						1,000,000
Common stock shares held in escrow | shares						200,000
Common stock escrow value						$ 10,000,000
Blockchain Mining Supply & Services Ltd [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate cash consideration						8,500,000
Purchase price on closing						7,000,000
Remainder of purchase price						1,500,000
Ingenium International LLC Consulting Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Obligation to pay for services						$ 4,000,000
Oklahoma Lease Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Monthly rent payment owed under lease agreement					$ 223,800
Increase in rent under lease				$ 665,760
Kairos Operations and Equipment Status [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Total cost for services			$ 300,000
Logical Brokerage Purchase Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate cash consideration				$ 600,000
Percentage of outstanding shares				92.50%
Ft. Lauderdale Lease Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Monthly rent payment owed under lease agreement	$ 7,000
Percentage Shares Owned in Kairos by Michael Ho [Member] | Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Ownership percentage									10.70%
Percentage Shares Owned in Kairos by Bryan Pascal [Member] | Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Ownership percentage									5.70%